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Abstract 
 
α-Isopropylmalate synthase (α-IPMS) is responsible for catalysing the first committed step in 
leucine biosynthesis. This pathway is found in plants and microorganisms, including pathogenic 
bacteria such as Mycobacterium tuberculosis and Neisseria meningitidis. α-IPMS catalyses a 
Claisen condensation reaction between α-ketoisovalerate (KIV) and acetyl coenzyme A (AcCoA) 
to form the product α-isopropylmalate (IPM). This enzyme undergoes feedback inhibition by 
the end product of the pathway, leucine. This regulation allows the control of the rate leucine 
biosynthesis.  
This project focuses on the α-IPMS enzymes from M. tuberculosis and N. meningitidis (MtuIPMS 
and NmeIPMS). These α-IPMS enzymes are homodimeric in structure. Each monomer consists 
of a catalytic domain which comprises of a (β/α)8 barrel fold, two subdomains and a regulatory 
domain, to which the allosteric binding of the natural inhibitor leucine occurs. The mechanism 
by which the allosteric binding of leucine leads to a decrease in enzymatic activity is not yet 
fully understood.  
Citramalate synthase (CMS) is responsible for catalysing the first committed step of threonine-
independent isoleucine biosynthesis. This enzyme is extremely similar to α-IPMS in both the 
reaction which it catalyses and the catalytic and regulatory domain structure. CMS catalyses a 
Claisen condensation reaction between pyruvate and AcCoA to produce citramalate (CM). CMS 
is also feedback inhibited by the end product of its pathway, isoleucine.  
The similarity between α-IPMS and CMS enzymes resulted in and examination of the inhibitor 
selectivity of MtuIPMS. Amino acids in the leucine binding site were altered to their 
counterparts in the isoleucine binding site of the CMS enzyme to see if the selectivity of the 
leucine binding site could be interchanged.  
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Results from this study show that it is possible to change inhibitor selectivity with a single 
amino acid substitution. However, changing the selectivity from leucine to isoleucine was 
unsuccessful. Instead, one of the MtuIPMS variants displayed significantly increased sensitivity 
to an alternative amino acid, norvaline. The MtuIPMS variants were expressed and purified 
using immobilised metal affinity chromatography and size-exclusion chromatography. These 
variants were then kinetically characterised and displayed similar binding affinities and turnover 
rates for the natural substrates to the wild-type enzyme. As expected changes to the leucine 
binding pocket had drastic effects on the sensitivity of the enzyme to its natural inhibitor. This 
work is described in Chapter 2 of this thesis.  
The mechanism by which the regulatory signal is transferred from the allosteric leucine binding 
site to the catalytic site in α-IPMS is not fully understood. NmeIPMS variants were created 
based on preliminary molecular dynamic simulations which indicated that significant changes in 
residue contacts were associated with leucine binding. Chapter 3 describes studies that explore 
the effect of single amino acid substitutions of NmeIPMS. The NmeIPMS variants were 
expressed and purified similarly to MtuIPMS, using immobilised metal affinity chromatography 
and size-exclusion chromatography. Variants were subsequently characterised via mass 
spectrometry, differential scanning fluorimetry and kinetic assays. It was found that each 
variant generated retained sensitivity to leucine but displayed significant differences in the 
catalytic efficiencies with AcCoA. One of the generated variants also displayed a significant 
increase in thermal stability. 
Results are drawn together in Chapter 4 along with future directions of this research. This 
chapter details knowledge gained into protein structure and allosteric mechanisms in this 
thesis. 
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Chapter 1 
Introduction 
1.1 Branched chain amino acid biosynthesis 
All organisms require a vast range of different key compounds and energy in order to function. 
These key molecules can be obtained by diet or by metabolic biosynthesis. Therefore each 
organism makes use of a complicated network of chemical reactions which are known as 
metabolic pathways. Humans are able to synthesise ten of the twenty common α-amino acids, 
which are used to build proteins, via key metabolic pathways.1,2 These ten amino acids which 
can be produced by humans are known as the non-essential amino acids. The other ten 
naturally occurring amino acids are known as the essential amino acids. Among the essential 
amino acids are the branched chain amino acids leucine, isoleucine and valine. Humans and 
other mammalian cells lack the metabolic machinery to produce the essential amino acids and 
need to obtain them from the environment, such as by ingesting and digesting proteins in food. 
While humans and other mammalian cells need to obtain the branched amino acids from the 
environment, bacteria3, fungi4 and plants5 are able to manufacture their own supply of these 
compounds using enzymes that function in metabolic pathways that are not present in 
mammalian cells. 
 
 
 
 
 
Figure 1.1: Chemical structures of the three branched chain amino acids. 
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As these essential amino acids are able to be manufactured in pathogenic bacteria such as 
Mycobacterium tuberculosis but not in human and other mammalian cells, this makes the 
metabolic pathways responsible for the production of these amino acids a viable target for drug 
design. If a key enzyme in a metabolic pathway is inhibited the enzyme is prevented from 
functioning and the end product can no longer be produced in the necessary quantity or 
obtained from the environment, the organism may die or undergo growth attenuation.6 
 
1.2 The isoleucine and valine biosynthetic pathway 
The initial starting compound for the biosynthesis of all three of the branched-chain amino 
acids is pyruvate. However, for the majority of bacteria and plants, the production of isoleucine 
also utilizes α-ketobutyrate (α-KB), which is derived from threonine.7 The enzyme which 
catalyses the formation of α-KB from threonine is known as threonine deaminase (TD). α-KB 
can also be formed via a threonine independent route in some bacteria; this is achieved via the 
citramalate pathway which will be discussed in detail.8 Isoleucine and valine are synthesised in 
similar ways and share a number of enzymes in their pathway (Figure 1.2) whereas the 
synthesis of leucine branches off from α-ketoisovalerate (α-KIV), which is the precursor for 
valine.9,10 The first committed steps in these pathways are all highly regulated by the branched-
chain amino acids being formed to ensure minimal metabolite waste. 
 
1.3 Valine and isoleucine synthesis 
The pathway for valine biosynthesis begins with the condensation of two molecules of pyruvate 
to form α-acetolactate (α-AL) via the enzyme acetohydroxy acid synthase (AHAS). AHAS is also 
responsible for the condensation of α-KB and pyruvate in the first committed step of the 
isoleucine biosynthesis pathway and is regulated by all three branched-chain amino acids.7,11 In 
some organisms a synergistic regulatory system exists where combinations of these three 
amino acids lead to differing levels of inhibition.7,11 The formation of valine and isoleucine run 
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in parallel from this point on, using the same enzymes to catalyse each transformation. The 
next enzyme involved in these pathways is responsible for the isomerisation and reduction of α-
acetolactate and α-acetohydroxybutyrate and is known as acetohydroxyacid isomeroreductase 
(AHAIR). These products are then dehydrated via dihydroxyacid dehydratase (DHAD) and then 
transaminated by branched-chain aminotransferase (BCAT) which forms the amino acid 
products.3 Both AHAIR and DHAD are also inhibited by valine and leucine in some organisms.11 
 
 
Figure 1.2: The branched-chain amino acid biosynthetic pathway where TD = threonine deaminase; 
AHAS = acetohydroxyacid synthase; AHAIR = acetohydroxyacid isomeroreductase; DHAD = 
dihydroxyacid dehydratase; BCAT = branched-chain aminotransferase. 
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1.4 The leucine biosynthetic pathway 
The first committed step in the biosynthesis of leucine is the condensation of α-KIV, which is 
one of the products near the end of the valine biosynthesis pathway,12 and acetyl coenzyme A 
(AcCoA) to form α-isopropylmalate (IPM) catalysed by the enzyme α-isopropylmalate synthase 
(α-IPMS). IPMS is feedback inhibited by the end product of the pathway, leucine. The next step 
is the transfer of a hydroxyl group between adjacent carbons on IPM via the enzyme 
isopropylmalate isomerase (IPMI) to form β-isopropylmalate. The new hydroxyl group is then 
oxidised to give the keto functionality while the other carboxylate group is removed to form α-
ketoisocaproate (α-KIC). Both these steps are catalysed by the enzyme β-isopropylmalate 
dehydrogenase (IPMD). The final step in the pathway is the transamination of α-KIC to form 
leucine.3 This reaction is performed by the BCAT enzyme responsible for the formation of is 
isoleucine and valine.  
 
  
 
 
 
 
 
Figure 1.3: The leucine biosynthesis pathway where α-IPMS = α-isopropylmalate synthase; IPMI = α-
isopropylmalate isomerase; IPMD = β-isopropylmalate dehydrogenase; BCAT = branched-chain 
aminotransferase. 
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1.5 The citramalate pathway 
As previously mentioned, the production of isoleucine can also be achieved via a threonine 
independent pathway in some organisms such as Leptospira interoggans13. This route is known 
as the citramalate synthase pathway. This pathway begins with the condensation of pyruvate 
and AcCoA which is catalysed by citramalate synthase (CMS) to form citramalate (CM). CMS is 
feedback regulated by isoleucine to control the flux through the pathway. The next step is a 
dehydration reaction via the enzyme 2-methylmalate hydrolyase (MMH) to form citraconate. 
MMH then hydroxylates citraconate to form 3-methylmalate which is further oxidized by 3-
methylmalate dehydrogenase (MMD) to form α-KB, the starting product seen in the threonine-
dependent pathway.14  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: The citramalate pathway. Where CMS = citramalate synthase; MMH = 2-methylmalate 
hydrolase; MMD = 3-methylmalate dehydrogenase; TD = Threonine deaminase. 
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1.6 α-Isopropylmalate synthase 
Overview 
α-IPMS (EC 2.3.3.13) catalyses the first committed step in the leucine biosynthesis pathway. 
The gene which encodes α-IPMS is known as leuA which in the case of Mycobacterium 
tuberculosis (Mtu) is polymorphic due to an insertion of a 57-base pair repeating unit which 
creates a variable number of tandem repeats.15 α-IPMS belongs to a family of enzymes known 
as Claisen-condensing enzymes. Claisen-condensing enzymes are responsible for the 
condensation reaction of AcCoA with α-keto acids. Other members of this family include 
citramalate synthase, which is introduced below, malate synthase, homocitrate synthase, re- 
and si-citrate synthases and methylthioalkylmalate synthase.16-19 All known α-IPMS enzymes 
require a divalent metal ion to polarize the carbonyl group of the α-keto acid, activating it for 
nucleophilic attack. 
A large range of α-IPMS enzymes have been studied from plants, fungi and bacteria. The most 
detailed studies on α-IPMS have been carried out on MtuIPMS as it is a viable drug target to 
slow or stop the growth of this pathogen.20 M. tuberculosis was also of interest as the leuA gene 
exhibits polymorphism, where a 57-base pair tandem repeating unit occurs between 2 and 21 
times. The number of tandem repeats does not affect the enzyme activity or expression and 
deletion of the repeat has no observed effect.21,22 The MtuIPMS used in this thesis was 
obtained from the H37Ra strain of M. tuberculosis, which contains two tandem repeats. 
1.6.1 Enzyme activity 
α-IPMS is responsible for the condensation of substrates AcCoA and α-KIV. Reported Km values 
for the natural substrates for α-IPMS from most organisms are typically between 5 and 600 µM 
with turnover numbers between 2 and 15 s-1 at pH levels between 7.0 and 8.0 (Table 1.1).23-28 
Slightly basic pH levels have been found to be most activating for this enzyme which may be 
due to deprotonation of AcCoA being a required step for catalysis as shown in the proposed 
mechanism (Figure 1.6). 
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Table 1.1: Kinetic data reported for α-IPMSs from different organisms where NR = not reported. 
Organism α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
M. tuberculosis23 12 136 3.5 
N. meningitidis24 30 35 13 
N. crassa25 10 25 NR 
S. cerevisiae26 16 9 NR 
S. typhimurium27 60 200 NR 
C. maltosa28 570 64 NR 
 
 
1.6.2 α-IPMS catalysed reaction and alternate substrates 
 
 
 
  
 
 
Figure 1.5: Reaction catalysed by α-IPMS. 
 
α-IPMS converts the substrates α-KIV and AcCoA into α-IPM and HCoA. α-IPMS has been 
observed functioning with a number of other α-keto acids such as pyruvate23, α-
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ketobutyrate23,25, α-ketovalerate23, α-ketoisocaproate and α-ketocaproate.29 Despite the 
promiscuity with α-keto acids strict adherence to AcCoA as the second substrate is observed. 
1.6.3 Alternate inhibitors 
As well as being able to catalyse reactions with other α-keto acids than the natural substrate, α-
IPMS is also inhibited by molecules other than the natural inhibitor, leucine. Some known 
alternate inhibitors for α-IPMS are: α-ketovalerate29, α-ketoisocaproate23, (S)-α-
hydroxyisovalerate23, valine25 and leucine halides.25 
1.6.4 Metal dependency 
All studied α-IPMS enzymes require a divalent metal ion for activity. The most common metal 
ion for obtaining the maximal enzyme activity is Mg2+.30,31 Effects on activity have been studied 
with various other divalent metal ions and it was discovered that metal ions which may activate 
the α-IPMS from one organism may have no effect or be inhibitory for the α-IPMS from other 
organisms.29-31 For example K+ ions are inhibitory for the α-IPMS from C. maltosa32. α-IPMS 
from some organisms such as MtuIPMS also require a monovalent cation, with the preference 
being for K+, although others such as Na+ are also activating. The monovalent cations have been 
shown not to directly affect the enzyme activity in MtuIPMS, but may instead act to recruit the 
divalent metal ions to the active site.30 
1.6.5 Proposed reaction mechanism 
The proposed mechanism of the condensation of α-KIV and AcCoA in MtuIPMS is shown in 
figure 1.6.23 The mechanism shows a divalent metal ion coordinating to the carbonyl groups of 
α-KIV withdrawing electron density from the carbonyl carbon. This makes the nucleophilic 
attack of AcCoA more favourable. Intermediate 2 is then nucleophillically attacked by water and 
subsequently loses the CoA group forming IPM. 
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Figure 1.6: Proposed mechanism for α-IPMS and CMS reactions. A is an acidic residue in the active site; 
B1 and B2 are basic residues in the active site. Mechanism proposed by de Carvalho et al.
23 
 
1.6.6 Structure 
The only full length structure which has been elucidated at this time is from M. tuberculosis 
(PDB codes 3HPS, 3HPZ, 3HQ1, 3FIG and 1SR9). Molecules which have been found bound in the 
active site of the enzyme in the crystals are α-KIV, α-KIC, bromopyruvate and citrate. At the 
regulatory domain only leucine has been shown bound. A variety of metal ions have also been 
found at the active site in the crystal structures, such as Zn2+, Mn2+, Ni2+ and Mg2+. There have 
been no full length structures solved without ligands bound yet suggesting the ligands may play 
a role in stabilising the enzyme leading to a more favourable conformation for crystallisation. 
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Figure 1.7: Crystal structure of α-IPMS from M. tuberculosis (PDB code 1SR9). One monomer is show in 
light grey while the other monomer is colour coded by domains and subdomains. The catalytic domain is 
shown in purple, subdomain I is in yellow, subdomain II is in red and the regulatory domain is blue. Α-KIV 
(cyan) and Zn2+ (black) are shown in the active site. 
 
The crystal structure of MtuIPMS (Figure 1.7) is known to form a dimer both in solution and 
when crystallised. The monomeric weight of MtuIPMS is 70 kDa. α-IPMS from other organisms 
have been reported to exist as trimer and tetramers.25,29 
Each MtuIPMS monomer is further divided into two domains, the catalytic and regulatory 
domains, and two subdomains, subdomain I and subdomain II. Between the two subdomains 
on each monomer is a flexible linker region which was not elucidated due to lack of electron 
density. The catalytic domain consists of a (β/α)8-barrel and contains the active site where the 
substrate and metal binding sites are located at the C-terminal of the barrel. Subdomain I 
consists of an α-helix and 2 beta sheets which cap the active site of the adjacent monomer and 
Catalytic domain 
Subdomain II 
Subdomain I 
Regulatory domain 
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may contribute residues involved in the binding of AcCoA. Subdomain I is then connected to 
subdomain II by the short unresolved linker region. The subdomain II is larger than subdomain I 
and consists of three α-helices. Finally the regulatory domain is comprised of a (βββα)2 fold 
which interlinks with the other monomer forming a sandwich in which two leucine molecules 
are able to bind at the interface between the monomers and allosterically inhibit the enzyme. 
The regulatory domain also contains two tandem repeats at the C-terminus corresponding to 
residues 575-612 which are flexible and undefined in the structure.15 
Interestingly, the monomers in MtuIPMS are not aligned symmetrically to one another, instead 
the catalytic domain and subunit I are rotated relative to each other (Figure 1.8).  
 
  
 
 
 
 
 
 
Figure 1.8: Crystal structure of MtuIPMS (PDB code 1SR9) showing the different conformations of the 
two monomers. The catalytic domain is shown in purple, subdomain I in yellow, subdomain II in red and 
the regulatory domain is shown in blue. 
 
12 
 
1.6.7 Feedback inhibition 
α-IPMS is feedback inhibited by leucine, the end product of the pathway.25 Since this is the 
enzyme responsible for catalysing the first committed step in the biosynthesis of leucine having 
feedback regulation allows for control of metabolite flux through the pathway in line with 
cellular requirements for leucine. 
Leucine binds to α-IPMS in the regulatory domain (Figure 1.10).33 Currently, it is unknown how 
the signal is carried through the enzyme and this is one of the aspects that is being examined in 
this thesis. In MtuIPMS, leucine inhibits similarly well in both substrate bound and unbound 
enzymes with a reported Ki value of 8 ± 1 µM and Ki’ value of 22 ± 2 µM.
34  
MtuIPMS also displays mixed inhibition which is slow-onset.35 The overall mechanism of slow-
onset inhibition for allosterically inhibited enzymes is still unclear. It is thought that the slow-
onset nature of inhibition in MtuIPMS is a consequence of a flexible loop which is involved in 
the binding of leucine.36 
As mentioned, it is unknown how the binding of leucine leads to inhibition of α-IPMS. Crystal 
structures show little difference between leucine-bound and unbound forms suggesting the 
enzyme is controlled by enzyme molecular dynamics. In order to examine possible differences 
in solvent accessibility between the leucine-bound and unbound forms solution-phase amide 
hydrogen/deuterium exchange was performed on MtuIPMS. This technique measures the 
incorporation of deuterium into the backbone amide hydrogens of proteolysed peptide 
fragments.37 Comparison of changes in deuterium uptake can be used to view dynamic changes 
which may be hidden or suppressed in crystal structures. 
Upon binding leucine the majority of difference in deuterium incorporation was found in the 
regulatory domain and in the region of subdomain II which interacts with the regulatory 
domain. It was found that the deuterium incorporation decreased upon leucine binding which 
corresponds to a conformational shift towards increased protection from solvent.38 
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Only residues 78-87 in the catalytic domain showed a change in deuterium exchange. This part 
of MtuIPMS contains Arg80 which binds to α-KIV and Asp81 which is involved in metal ion 
coordination. Examination of the Y410F variant of MtuIPMS also exhibits a decrease in 
deuterium exchange of these residues.38 The Y410F variant maintains the ability to bind leucine 
with a KD of 21 ± 1 µM but has a catalytic rate similar to maximally inhibited wild-type 
MtuIPMS.39 
These experiments indicate important regions involved in the regulatory signal transfer, 
however it still remains unclear exactly how regulation is achieved. 
 
1.7 Ligand binding in Mycobacterium tuberculosis 
1.7.1 α-KIV binding 
 
 
 
 
 
Figure 1.9: Active site of MtuIPMS (PDB code 1SR9) with α-KIV (cyan) shown interacting with Zn2+ 
(black). Residues involved in binding α-KIV and Zn2+ are also shown in purple. Water is shown as a sphere 
in yellow. 
 
H285 D81 
R80 
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The active site of MtuIPMS (viewed as PDB code 1SR9, Figure 1.9) consists of a metal ion 
coordinating to α-KIV. The metal ion, in this case Zn2+, is held in place by coordination to a 
water molecule and the residues Asp81, His285 and His287. The divalent metal ion polarizes 
the α-KIV making it more susceptible to nucleophilic attack as shown in the proposed reaction 
mechanism (Figure 1.6). Monovalent metal ions have not been observed in the crystal structure 
suggesting that they do not play a role in the physical binding of the substrates. As well as 
coordination to the divalent metal ion, α-KIV also interacts with the residues R80 and T284. The 
active sites of α-IPMSs are highly conserved. Asp81, His285, Arg80 and Thr254 are all conserved 
across the range of α-IPMSs. A hydrophobic pocket is also present around α-KIV which is 
thought to dictate the enzyme’s specificity for the α-keto acid. The residues involved in the 
formation of the hydrophobic pocket are Leu143, His167, Ser126, Asn250 and pro252, all of 
which are highly conserved. 
 
1.7.2 Leucine binding 
 
 
 
 
 
Figure 1.10: Interface between monomers of the regulatory domain of MtuIPMS (PDB code 3FIG). 
Shows residues from each monomer (orange and cyan) binding to leucine (yellow). 
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α-IPMS is allosterically inhibited by a leucine molecule in each monomer, which are found 
bound at the regulatory domain. The regulatory binding site of MtuIPMS (PDB code 3FIG) 
(figure 1.10) consists of interactions between Asn532 and Leu535 from one monomer and 
Ala565 and Ile627 from the other monomer. A hydrophobic binding pocket around the 
hydrophobic end of leucine is formed by residues Val551, Leu535 and Tyr554. 
Residues in the regulatory site of α-IPMS are well conserved. The motif G-x-G-P-[VIL] is known 
where x can be any residue. The motif corresponds to residues 531-535 in MtuIPMS. 
 
1.8 MtuIPMS truncation 
 
 
 
 
 
 
Figure 1.11: Crystal structure of the truncated MtuIPMS (PDB code 3U6W) showing the catalytic domain. 
Each domain is shown as different colours. 
 
A truncated variant of MtuIPMS was also created in which the catalytic domain was isolated 
and characterised.40 The protein is comprised of residues 1-425 of the wild-type enzyme that 
corresponds to the catalytic domain and subdomain I therefore excluding the regulatory 
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domain and subdomain II. The protein had a molecular mass of 47.5 kDa as compared to the 
wild type mass of 70 kDa. It was determined that MtuIPMS existed as a homodimer in solution 
using size-exclusion chromatography and the protein was found to be a homodimer in the 
crystalline form. A slight loss of thermal stability was observed using differential scanning 
fluorimetry (DSF) where the melting point of the truncated variant was decreased from the 
wild-type value of 42.5 ± 0.1 °C to 40.8 ± 0.1 °C. Kinetic studies showed no catalytic activity for 
this truncated variant. 
 
1.9 NmeIPMS truncation 
 
 
 
 
 
 
Figure 1.12: Crystal structure of truncated NmeIPMS (PDB code 3RMJ) showing the catalytic domain. 
The two monomers are shown in different colours. 
 
A truncated variant of the α-IPMS from Neisseria meningitidis (Nme) was created in which the 
catalytic domain was isolated and characterised. There is currently no full length structure 
available for this variant. The protein is made up of residues 1-365 of the NmeIPMS which is 
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comprised of the catalytic domain, subdomain I and two α-helices of subdomain II and had a 
molecular mass of 40 kDa. The full length protein has a mass of 56 kDa. Size-exclusion 
chromatography indicated that the truncated variant was homodimeric despite the significant 
loss of potential contacting residues due to the truncation. It was shown using DSF that the 
truncated variant had the same melting point as the wild-type enzyme of 44.5 ± 0.1 °C 
suggesting the regulatory domain does not add to the stability of the enzyme. The enzyme 
displayed AcCoA hydrolysis in the absence of α-KIV, but was unable to catalyse the Claisen-
condensation between α-KIV and AcCoA. AcCoA hydrolysis was not affected by leucine 
concentrations up to 10 mM as was expected with a lack of the regulatory domain.  
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1.10 Citramalate synthase 
1.10.1 Overview 
Citramalate synthase (CMS), an enzyme found in the citramalate pathway, is one of the key 
enzymes responsible for the creation of isoleucine via the threonine-independent pathway 
found in archaea and some bacteria such as Leptospira interrogans (Li), which is the causative 
agent for Zoonotic disease. This enzyme also catalyses a Claisen-condensation reaction similar 
to α-IPMS.41  
Only a small number of CMS enzymes have been studied as this pathway is relatively rare due 
to most organisms using the threonine-dependent pathway for isoleucine synthesis. CMS has 
been studied in L. interrogans41, G. sulfurreducens42, M. sannaschii43, R. rubrum44 and 
Thermoanaerobacter sp.45 
 
1.10.2 Enzyme activity 
CMS is responsible for the condensation reaction of AcCoA and pyruvate to form citramalate 
(Figure 1.13). Reported Km values for the natural substrates vary significantly (Table 1.2). 
Slightly basic pH levels have been shown to lead to the greatest enzyme activities with most 
assays being performed between pH 7.0 and 8.0. 
 
Table 1.2: Kinetic data for CMS from different organisms. NR = not reported. 
Organism Pyruvate Km (µM) AcCoA Km (µM) kcat (s
-1) 
L. interrogans41 60 1118 10.3 
R. rubrum44 NR 3200 NR 
M. jannaschii43 184 303 0.36 
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LiCMS is able to use glyoxalate and α-KB as alternate α-keto acid substrates but exhibits no 
observable activity with α-KIV, the substrate for α-IPMS.41 
 
1.10.3 Catalysed reaction 
 
 
 
 
 
 
 
 
Figure 1.13: Reaction catalysed by CMS 
 
1.10.4 Metal dependency 
Like α-IPMS, LiCMS requires a divalent metal ion for catalysis. Unlike MtuIPMS monovalent 
cations are not essential for activity, however, when K+ ions are added a ~50 % increase in 
activity is observed.41 It is thought the K+ ions stimulate the divalent metal ions in the active 
site. 
1.10.5 Proposed mechanism 
The mechanism proposed for the condensation of AcCoA and pyruvate by LiCMS is analogous to 
the mechanism proposed for IPMS catalysis (Figure 1.6).  
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1.10.6 Feedback inhibition 
CMS is allosterically feedback regulated by the end product of its pathway, isoleucine. This 
allows for control of the metabolic flux throughout the pathway ensuring over-production of 
isoleucine does not occur. Isoleucine binds and inhibits the enzymes at an allosteric position in 
the regulatory domain. LiCMS has a reported Ki of 19 ± 5 µM for isoleucine and no inhibition 
observed with leucine. Two LiCMS mutants have been created which show some inhibition by 
leucine. These are Y454A and V468A which have respective Ki values of 1302 ± 406 µM and 75 ± 
24 µM.13 
1.11 Structure 
There are currently no full length crystal structures solved of CMS from any source. Only five 
crystal structures of parts of the protein have been solved so far (PDB codes 3F6G, 3F6H, 3BLF, 
3BLE and 3BLI) and all of these are from L. interrogans. Two of these structures are for the 
regulatory domain complexed with isoleucine at the regulatory site, and one of these structures 
also contains sulfate. The other three structures show the catalytic domain complexed with 
malonate, pyruvate or pyruvate and AcCoA with Zn2+ as the metal ion. 
 
 
 
 
 
Figure 1.14: Catalytic domain of LiCMS (PDB code 3BLI) with α-KIV (yellow) and AcCoA (orange) bound. 
Zn2+ (black) is shown as the divalent metal ion. 
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The full length LiCMS is comprised of 516 amino acids with a molecular mass of 56 kDa for each 
monomer. The crystal structure of the regulatory domain shows LiCMS as a homodimer. LiCMS 
appears to be comprised of an N-terminal catalytic domain (residues 1-330) and a C-terminal 
regulatory domain (residues 390-516) which based on homology models with MtuIPMS are 
thought to be connected via a flexible linker region (residues 331-389). The catalytic domain is 
composed of a (β/α)8-barrel as with MtuIPMS. The regulatory domain adopts a (βαβ) sandwich 
structure made of two anti-parallel β-sheets and two α-helices. The inhibitor binding pocket is 
located in the same place as it is on MtuIPMS, at the dimer interface.  
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Regulatory domain of LiCMS (PDB code 3F6G) showing isoleucine (cyan) bound. One 
monomer is shown in red and the other in grey. 
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1.11.1 Pyruvate binding 
 
 
 
 
 
 
 
Figure 1.16: Catalytic domain of LiCMS (PDB code 3BLI) showing the active site with pyruvate (yellow) 
interacting with Zn2+ (black) and important active site residues (cyan). The water molecule is shown as a 
yellow sphere. 
 
Pyruvate binds at the active site of LiCMS near the N-terminus. A Zn2+ ion interacts with the 
carbonyl and carboxylate functional groups withdrawing electron density which allows for a 
more favourable nucleophilic attack from AcCoA. The Zn2+ ion is held in place by three residues 
- Asp17, His207 and His209. Asp16 is also able to hydrogen bond pyruvate which may help to 
stabilise pyruvate binding. 
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1.11.2 AcCoA binding 
No structure with AcCoA bound to α-IPMS has been solved. The catalytic domain of LiCMS does 
however show both pyruvate and AcCoA bound in the active site. Figure 1.17 shows the overlay 
of MtuIPMS with LiCMS illustrating residues which play a similar role in substrate binding and 
suggest a location in MtuIPMS where AcCoA is likely to bind. There are many similarities in the 
active sites of these two enzymes. The LiCMS residues Arg16, Asp17, His207, His209 and Thr179 
are also found in almost identical places in MtuIPMS suggesting these residues are extremely 
important in the condensation of α-keto acids and AcCoA. Glu146 is thought to act as a base 
which enolises AcCoA while Arg16 stabilises the enol form.13 These residues are highly 
conserved for both enzymes.  
 
 
 
 
 
 
Figure 1.17: Overlay of the active site of LiCMS (blue)(PDB code 3BLI) and MtuIPMS (purple)(PDB code 
1SR9). AcCoA is shown in orange, α-KIV in cyan, pyruvate in yellow. Zn2+ in LiCMS is shown in black and 
in MtuIPMS in grey. CMS hydrogen bonding is shown. 
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1.11.3 Isoleucine binding 
 
 
 
 
 
 
 
 
 
Figure 1.18: LiCMS (PDB code 3F6G) regulatory site showing isoleucine (cyan) binding at the dimer 
interface. One monomer is shown in grey and the other in red.  
 
 
LiCMS forms hydrogen bonds with residues Asp431, Thr464, Ala466 and Gln495. The selectivity 
towards isoleucine over other ligands is also influenced by hydrophobic interactions which is 
the work described in chapter 2. The residues Thr464 and Ala466 are located on a flexible β-
strand which is thought to play a role in ‘capping’ the regulatory pocket when isoleucine is 
bound. The same ‘capping’ strand is found in the MtuIPMS structure (Figure 1.19).36 
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Figure 1.19: Regulatory domains of MtuIPMS (blue)(PDB code 3FIG) and LiCMS (red)(PDB code 3F6G) 
overlaid illustrating the flexible ‘capping’ β-strand in yellow (MtuIPMS) and green (LiCMS). Leucine is 
shown in cyan and isoleucine in orange. 
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1.12 Objectives of this thesis 
 
The main objective of this thesis was to investigate the determinants of the inhibitor selectivity 
in MtuIPMS from leucine and gain an understanding of the role the residues in the regulatory 
binding pocket play in inhibitor selectivity. A change in inhibitor selectivity from leucine to 
isoleucine was attempted based upon the regulatory site of LiCMS. This work was carried out 
using α-IPMS from M. tuberculosis. 
 
The secondary objective in this thesis was to investigate three residues which were thought to 
be involved in the transmission of the regulatory signal from the regulatory domain through the 
enzyme to the catalytic domain. This part of the thesis was carried out using α-IPMS from N. 
meningitidis. 
 
Research goals: 
 
  Gain a greater understanding of how inhibitor selectivity is determined 
  Increase the knowledge of α-IPMS enzymes and the roles they play 
 Gain an understanding of how the regulatory signal may be transferred throughout the 
protein with minimal conformational change 
 
α-IPMS from M. tuberculosis and N. meningitidis were chosen due to the pathogenic nature of 
the organisms they originate from and their availability. A range of amino acid substituted 
variants were created to investigate inhibitor selectivity and regulatory signal transfer. 
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Chapter 2 
Effects of regulatory domain variants on 
inhibitor selectivity of α-isopropylmalate 
synthase from Mycobacterium tuberculosis 
 
2.1 Overview 
 
The goal of this research was to make single amino-acid changes to the allosteric inhibitory site 
of MtuIPMS in order to see if inhibitor selectivity could be tuned towards isoleucine over the 
natural inhibitor leucine.  
These variants were characterised via enzyme kinetic studies, protein mass spectrometry, 
differential scanning fluorimetry and circular dichroism. Enzyme kinetic studies included 
obtaining Michaelis-Menten constants and determining the relative inhibition data for each 
variant generated. Protein mass spectrometry was implemented to ensure the purified protein 
was of the correct mass. Differential scanning fluorimetry was used to determine the melting 
temperatures of the wild-type and each variant in the presence of different inhibitors and in 
the absence of inhibitor. Finally circular dichroism was used to ensure the chosen variants did 
not significantly alter the secondary structure of the enzyme via comparison to the wild-type 
enzyme. 
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2.2 Design of MtuIPMS variants 
In order to change the MtuIPMS inhibitor selectivity from leucine to isoleucine, the isoleucine-
sensitive enzyme that is responsible for catalysing a similar reaction to α-IPMS, CMS, was used 
as a template. The crystal structure of the regulatory domain of the only currently described 
CMS structure, LiCMS, was overlaid with the MtuIPMS regulatory domain crystal structure to 
make structural comparisons.13,33 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Superposition of the regulatory domains from MtuIPMS (blue, PDB code 3FIG) and LiCMS 
(red, PDB code 3F6G) showing natural inhibitors leucine (cyan) and isoleucine (orange) bound. 
 
This overlay shows a high similarity in tertiary structure and subunit interaction between IPMS 
and CMS enzymes and illustrates the similar binding poses and positions of the inhibitors. A 
closer analysis of the binding sites in LiCMS was carried out to reveal differences and similarities 
in key residues involved in the hydrophobicity of the regulatory pocket (Figure 2.2). 
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Figure 2.2: Residues contributing to the regulatory pockets of MtuIPMS (PDB code 3FIG) and LiCMS (PDB 
code 3F6G). Leucine is shown in cyan, and isoleucine in orange. Residues for LiCMS are shown in yellow 
for one monomer and orange for the opposing monomer. MtuIPMS residues are shown in cyan for one 
monomer and blue for the other. Residue labels for LiCMS are coloured black and grey for MtuIPMS. 
 
By comparing the residues involved in binding isoleucine in LiCMS with the residues involved in 
binding leucine in MtuIPMS, the following residues in MtuIPMS were selected as potential 
residues for mutation for further analysis: V551, A558, A567 and I627. 
 
Table 2.1: Distance of chosen residues from the bound leucine in the regulatory domain of MtuIPMS 
(PDB code 3FIG). 
MtuIPMS residue Nearest distance from bound leucine (Å) 
Val551 4.3 
Ala558 4.1 
Ala567 4.4 
Ile627 3.9 
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Q495 
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A536 
Y430 
L535 
T464 
D563 
L451 
V551 
I458 
A558 
Y454 
Y554 
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The chosen residues were then analysed further by inspecting a multiple sequence alignment 
(Appendix A) of α-IPMS sequences in order to ensure the residues chosen are well conserved 
across the α-IPMS enzymes (Table 2.2), suggesting they play an important role in the binding of 
leucine. A comparable multiple sequence alignment of CMS enzymes was not carried out as it 
was not clear which of the sequences annotated as CMS are in fact CMS enzymes. 
 
Table 2.2: Residues in LiCMS that correspond to the chosen residues in MtuIPMS and conservation of 
these residues across α-IPMS enzymes. 
MtuIPMS residue LiCMS residue Conserved in α-IPMS (Yes/No) 
Val551 Leu451 Yes  
Ala558 Ile458 Yes  
Ala567 Val468 Yes  
Ile627 Gln495 Yes (Ile or Thr) 
 
 
2.3 Justification of choice of variants 
 
2.3.1 MtuIPMS A558I and A558V 
The Ala558 residue of MtuIPMS is well conserved across α-IPMS enzymes in the multiple 
sequence alignment. All but one α-IPMS enzyme in the multiple sequence alignment (Appendix 
A) have an alanine at this position. The other residue observed at this position is threonine. The 
mutation to an isoleucine was performed to mimic the residue in the same position in LiCMS. 
Ala558 was also changed to valine in case the introduction of an isoleucine at this position led 
to an unstable regulatory site due to steric factors possibly preventing inhibitors being able to 
bind to the regulatory site or due to interactions with the side chains of neighbouring residues. 
 
 
32 
 
2.3.2 MtuIPMS V551L 
The Val511 residue of MtuIPMS is well conserved. There are two enzymes in the multiple 
sequence alignment which contain an isoleucine and a leucine at this position. The 
corresponding residue at this position in LiCMS is a leucine. The mutation from valine to leucine 
was carried out to mimic the LiCMS regulatory site. 
2.3.3 MtuIPMS A567V 
The Ala567 residue of MtuIPMS is conserved across α-IPMS enzymes in the multiple sequence 
alignment. Ala567 corresponds to a valine in LiCMS, and was mutated into a valine to mimic 
LiCMS. 
2.3.4 MtuIPMS I627A 
The Ile627 residue of MtuIPMS is conserved as an isoleucine or threonine across α-IPMS 
enzymes. Based upon the crystal structure it was substituted for an alanine to determine the 
effect of shortening the side chain at this position and potentially to make room for the methyl 
group at the C3 position of isoleucine. This residue was not exchanged for glutamine (the 
equivalent residue in LiCMS) due to the high possibility of steric classes with other residues 
within the regulatory pocket resulting from increased chain length. 
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2.4 MtuIPMS variant generation using PCR 
MtuIPMS variants were created via the mutation of the wild-type MtuIPMS gene using a 
polymerase chain reaction (PCR) method. The MtuIPMS wild-type gene was located in pPROEX-
HTa plasmid. This plasmid also contains coding for an N-terminal His-tag to allow for easy 
purification by immobilised metal affinity chromatography, a TEV protease cleavage sequence 
located between the MtuIPMS gene and the His-tag sequence to allow for tag removal after 
purification, a T7 promoter region binding a lac operon to enable over-expression of the protein 
of interest after addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) and an ampicillin 
resistance gene to allow for selection of cells containing the plasmid during growth on media 
containing ampicillin. A plasmid extraction was carried out to obtain the plasmid containing the 
wild-type MtuIPMS gene. The purified plasmid was then examined on an agarose gel to ensure 
the obtained plasmid was the expected size of approximately 4700 bp. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Agarose gel showing purified pPROEX-HTa plasmid which contains the wild-type MtuIPMS 
gene. Marker weights shown are in base pairs (bp). 
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Once the wild-type template DNA was obtained PCR was performed using primers which were 
designed to introduce the mutations of choice into the wild-type gene. The amplified PCR 
products were subjected to the addition of Dpn1 which digests the methylated wild-type 
template DNA leaving only the amplified PCR product which containing the mutation. 
The PCR products were then analysed using agarose gel electrophoresis to ensure a band 
corresponding to the theoretical calculated size of the PCR product had been obtained. 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Agarose gel showing PCR products post Dpn1 treatment. Lane 1, A558V; lane 2, V551L; lane 
3, ladder of which marker weights are shown in base pairs; lane 4, A567V and lane 5, I627A. Marker 
weights above 5000 are not shown for viewing clarity. Each marker band above 5000 is another 1000 bp 
where the largest band corresponds to 12000 bp. 
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MtuIPMS 
Once the PCR product had been viewed as the correct size on agarose gel transformation into E. 
coli One Shot TOP10 cells was performed. The plasmids were then isolated from the cells and 
sequenced. The sequences were compared to the wild-type gene sequence to ensure that the 
PCR had been successful and the correct mutation had been introduced into the gene. The 
plasmids which contained the mutations of interest were then transformed into BL21(DE3)Star 
cells for protein expression. 
2.5 Expression of protein 
Expression of the wild-type MtuIPMS and variants was carried out as described in the materials 
and methods section (Chapter 5). Following cell growth and protein expression, cell pellets 
were stored at -80°C until required. Proteolysis can occur in the cell lysate during purification 
steps. To minimize this, immobilised metal affinity chromatography (IMAC) steps were 
performed immediately after lysis and protease inhibitor was added to the lysate. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: SDS-PAGE gel of wild-type MtuIPMS over-expression after lysis using BugBuster® showing the 
supernatant (SN) in lane 1 and the cell pellet (CP) in lane 2 with ladder shown in lane 3. Marker weights 
indicated are in kDa. 
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Cell lysis was performed using sonication for full scale cell growths or using detergent based 
disruption (Bugbuster®) for small scale growths such as expression trials. A large proportion of 
the over-expressed protein is found in the supernatant at the expected molecular mass of 77 
kDa which also includes the 4 kDa His-tag. Due to the presence of many other proteins 
observed in the cell pellet it appears that lysis is incomplete. 
 
2.6 Purification 
The wild-type MtuIPMS and mutants were purified using the method shown in figure 2.6.40  
 
 
 
 
 
 
 
 
Figure 2.6: Flow diagram of the procedure used for purification of MtuIPMS. 
 
This purification procedure produced protein of high purity for all characterisation assays. 
Dithiothreitol (DTT) was added prior to addition of TEV protease in order to reduce disulfide 
bonds which may form between the proteins allowing for better access to the TEV cleavage 
site. The dilution with SEC buffer following the IMAC step was performed to reduce imidazole 
concentration in preparation for TEV protease cleavage of the His-tag. 
This purification procedure usually yielded 10-15 mg of purified protein for a 1 L cell culture 
grown in lysogeny broth (LB). 
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2.6.1 Immobilised metal affinity chromatography 
The first step in the purification procedure of MtuIPMS is IMAC. A HisTrap charged with Ni2+ 
ions was used to separate MtuIPMS from background E. coli proteins via the N-terminal His-tag. 
Protein which bound to the column was eluted with imidazole. The bound and unbound 
fractions typically obtained from this procedure can be viewed in lanes 1 and 2 of figure 2.8. 
2.6.2 Desalting 
Protein was eluted from the IMAC column in a buffer which contained a high imidazole 
concentration. For this reason, prior to the addition of TEV protease, the pooled fractions were 
diluted in SEC buffer containing no imidazole to ensure the imidazole did not interfere with 
protein stability or TEV protease efficiency. 
2.6.3 TEV protease cleavage 
Once the desalting step had been completed the protein was digested with TEV protease 
overnight at 4°C to remove the N-terminal His-tag. Removal of the His-tag was carried out to 
minimise the chances of the tag interfering with the characterisation of MtuIPMS. 
The His-tag added 25 residues to the N-terminus of MtuIPMS including the six histidine residues 
used to bind the protein to the IMAC column and the TEV protease recognition sequence. After 
digestion two residues (glycine and alanine) are left attached to the N-terminus of MtuIPMS 
(Figure 2.7). 
 
         P F V Y H H H H H H D Y D I P T T E N L Y F Q G A M A T S E S 
 
Figure 2.7: Sequence of the pPROEX-HTa plasmid polyhistidine tag showing the polyhistidine tag (red), 
the TEV recognition site (green) the extra residues after digestion (blue) and the beginning of the 
MtuIPMS sequence (pink). 
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After digestion was complete the solution was once again run through the HisTrap column, 
which allowed the His-tag cleaved protein to travel through the column without binding. The 
TEV protease contains a His-tag so that it binds to the column separating it from MtuIPMS. An 
example of the bound and unbound fractions from this step are shown in figure 2.8. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: SDS-PAGE gel showing fractions after each IMAC step for MtuIPMS I627A. Lane 1, shows the 
flowthrough from the first IMAC run; lane 2, shows the bound fraction from the first IMAC run; lane 3, 
shows the marker ladder; lane 4 and 5, show the flowthrough of the second IMAC run and lane 6, shows 
the bound fraction of the second IMAC run. Indicated marker weights are in kDa. 
 
2.6.4 Size-exclusion chromatography 
The last step in the purification protocol was size-exclusion chromatography (SEC), which elutes 
MtuIPMS in one peak and aggregated proteins in a separate peak which has a smaller retention 
volume. The mass of the purified protein was that of the expected molecular mass of 70 kDa 
(Figure 2.9). 
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Figure 2.9: SDS-PAGE gel of final collected fractions after SEC of wild-type MtuIPMS and variants. Lane 1, 
shows the marker ladder; lane 2, shows the wild-type; lane 3, shows A558I; lane 4, shows A558V; lane 5, 
shows V551L; lane 6, shows A567V and lane 7, shows I627A. Marker weights are shown in kDa. 
 
2.7 Mass spectrometry 
The masses of all the MtuIPMS enzymes were measured using electrospray mass spectrometry 
(MS) to ensure all enzymes were of the expected mass calculated from amino acid sequence 
using ProtParam. A summary of the wild-type and variant masses is shown in table 2.3. 
 
Table 2.3: Expected masses and masses calculated via MS of MtuIPMS enzymes. 
Enzyme Expected mass (Da) Calculated mass (Da) 
MtuIPMS WT 70211.7 70212.6 
MtuIPMS A558I 70253.8 70252.7 
MtuIPMS A558V 70239.7 70237.2 
MtuIPMS V551L 70225.7 70227.3 
MtuIPMS A567V 70239.7 70237.8 
MtuIPMS I627A 70169.6 70169.9 
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2.8 MtuIPMS wild-type 
 
2.8.1 Physical characterisation 
This section details the examination of the wild-type enzyme. This work took place for later 
comparison with the MtuIPMS variants. 
2.8.2 Secondary structure analysis 
A circular dichroism (CD) spectrum (Figure 2.10) was obtained for MtuIPMS wild-type enzyme 
to ensure  the protein was folded correctly and to use as a comparison for the MtuIPMS 
variants to ensure no major structural change had taken place. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Circular dichroism spectrum of MtuIPMS wild-type. Spectrum was obtained using 0.2 
mg/mL protein in distilled H2O at pH 7.0.  
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The shape of the obtained spectrum is consistent with the shape of the properly folded protein. 
This presence of secondary structure suggests it is suitable for further characterisation. 
2.8.3 Thermal stability 
Differential scanning fluorimetry (DSF) was used to examine the thermal stability of the wild-
type enzyme and the effects which occurred to the denaturation temperature in the presence 
of the inhibitors leucine, isoleucine and norvaline. DSF uses a dye which binds to hydrophobic 
regions of the protein and fluoresces. As the protein is subjected to steady heating it reaches a 
point where it denatures revealing previously buried hydrophobic regions leading to a steep 
rise in the fluorescence intensity. This allows the denaturation point of the enzyme to be 
calculated by plotting the differentiated function and looking for the lowest point on the graph 
(Figure 2.11).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Example of a DSF curve for the wild-type MtuIPMS enzyme with no ligand present where in 
green is the relative fluorescence unit (RFU) and shown in purple is the negative derivative of the RFU. 
Red shows the negative control which contains no enzyme. The melting temperature is expressed as the 
steepest part of the RFU trace and the minimum on the negative derivative. The experiment was carried 
out in BTP buffer at pH 8.0. 
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It was found using DFS that wild-type MtuIPMS has a denaturation temperature of 47.6 ± 0.1 °C 
which is similar to the denaturation temperature (Tm) obtained for the IPMS from N. 
meningitidis (Figure 3.9).24 
DSF can be used as evidence for ligand binding as when a ligand binds to the protein an overall 
increase in the stability is sometimes observed.46 Responses to the thermal stability of the wild-
type enzyme when in the presence of 5 mM leucine, isoleucine and norvaline are displayed in 
figure 2.12. 
 
Figure 2.12: Effects on Tm of MtuIPMS in the presence of 5 mM leucine, isoleucine and norvaline in 25 
mM BTP buffer (pH 8.0). 
 
From this data a small but significant increase in the thermal stability of the protein was 
observed in the presence of all three ligands, suggesting that the enzyme is stabilised by all of 
the tested ligands. Leucine was expected to provide the greatest increase in stability due to its 
role as the natural inhibitor of MtuIPMS and this was observed, however, norvaline was found 
to stabilise the enzyme to almost the same extent. Isoleucine did stabilise the enzyme but to a 
lesser degree. The tested concentrations of tested ligands were very high compared to the in 
vivo concentrations, and this may have led to fully occupied regulatory binding sites with the 
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tested ligands despite having a low binding affinity, leading to a lack of discrimination between 
different ligands at this concentration.  
2.8.4 Kinetic characterisation 
The activity of MtuIPMS was studied first by finding the apparent Michaelis-Menten constants 
for the two substrates (α-KIV and AcCoA). Once this data had been elucidated, assays involving 
leucine, isoleucine and norvaline were performed. 
All assays were carried out using a 4,4’-dithiodipyridine (DTP) coupled assay which was 
monitored at 324 nm. This measures the formation of a thio-pyridine as DTP reacts with the 
free thiol group of the enzyme reaction product CoA.34 
2.8.5 Michaelis-Menten kinetics 
Apparent Km and turnover values were measured at 25 °C and pH 8.0. Apparent AcCoA Km 
values were found by holding the α-KIV concentration at 400 µM while the AcCoA 
concentration was varied from low to high concentrations. The apparent α-KIV Km values were 
determined by holding the AcCoA concentration at 300 µM while the α-KIV was varied from low 
to high concentration. Km values of 41 ± 2 µM and 8.4 ± 0.9 µM were calculated for AcCoA and 
α-KIV respectively. A kcat value of 3.6 ± 0.1 s
-1 was also obtained for the wild-type enzyme 
(Figure 2.13). 
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Figure 2.13: Michaelis-Menten plots obtained for wild-type MtuIPMS showing the apparent AcCoA (left) 
and α-KIV (right) Km. Standard assay conditions were as follows: 500 µM DTP, 3 mM MgCl2 and 20 mM 
KCl. A kcat value of 3.6 ± 0.1 s
-1 was obtained. 
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2.8.6 Allosteric inhibition based upon initial rates 
 
 
 
 
 
 
 
 
 
Figure 2.14: Remaining activity (%) of MtuIPMS wild-type in the presence of differing concentrations of 
leucine, isoleucine and norvaline when initial rates are measured. Experimental conditions as follows: 
500 µM AcCoA, 400 µM α-KIV, 500 µM DTP, 20 mM KCl and 3 mM MgCl2 in 50 mM Tris-HCl buffer at pH 
8.0. 
The activity of MtuIPMS in the presence of leucine at 500 µM is maximally inhibited and the 
activity drops to approximately 15 % of the uninhibited activity and remains at this level as the 
leucine concentration is increased. This high level of inhibition was expected as leucine is the 
natural inhibitor for the wild-type enzyme. Little effect on the activity of the enzyme at 1 mM 
isoleucine was observed. However, at 5 mM a decrease in activity to approximately 38 % was 
observed. The relative insensitivity of the enzyme to the lower leucine concentration suggests 
that isoleucine inhibition may not be physiologically relevant in vivo; otherwise leucine 
production would be highly dependent upon intracellular isoleucine levels. MtuIPMS shows a 
similar sensitivity towards norvaline where at 1 mM a slight decrease in activity was observed 
and when the concentration was increased to 5 mM the enzyme activity dropped to 
approximately 44%. 
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2.9 Demonstration of slow-onset inhibition 
MtuIPMS displays a rare type of inhibition in which a time-dependent effect on rate is 
observed, this is known as allosteric slow-onset inhibition. It is thought that this is due to 
MtuIPMS acting through a two-step mechanism where equilibrium exists between two 
conformations of the enzyme-inhibitor complex. These two conformations display different 
kinetic properties and are separated by an energy barrier.36,46 
 
 
 
 
 
  
 
Figure 2.15: Diagram showing energy profile for allosteric slow-onset inhibition where E = Unbound 
enzyme; EI = High energy enzyme-inhibitor complex transition state; EI* = Low energy enzyme-inhibitor 
complex. 
 
Data to examine the slow onset inhibition was obtained for the wild-type MtuIPMS (Figure 
2.16). Allosteric slow-onset inhibition was observed at all tested leucine concentrations. 
Reaction rates measured after two minutes were slightly lower than the initial rates. This 
behaviour was not a result of decreasing substrate concentrations as the reaction progressed, 
as this change in rate was not seen with the uninhibited enzyme over this time course or 
reaction extent. Interestingly slow-onset kinetics was observed with all tested ligands which 
disagrees with results published recently by Casey et al36 where show onset inhibition was only 
observed with leucine. This effect may arise from the relatively high ligand concentrations used 
in the assays. 
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2.9.1 MtuIPMS wild-type observed slow-onset inhibition 
 
Figure 2.16: Observed slow-onset allosteric inhibition of MtuIPMS wild-type with differing 
concentrations with tested inhibitors. Shown in blue are remaining activity percentages based upon 
initial rates measured. Shown in red is the remaining activity percentage of rates measured two minutes 
after reaction initiation. 
 
The data obtained by measuring the initial rates and the rates after two minutes shows that the 
wild-type MtuIPMS enzyme displays slow-onset inhibition with all three tested ligands. Similar 
decreases in the remaining activity percentages are seen between the initial and two minute 
measurements for all leucine concentrations and isoleucine at 5 mM. Norvaline showed a much 
larger difference in remaining activity percentage, dropping from 45 % to under 30 % in two 
minutes. 
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2.10 Variant structure analysis 
To ensure no major structural changes had taken place due to the introduced amino acid 
substitutions, CD spectra were obtained for MtuIPMS variants and these were compared to the 
spectrum obtained for the wild-type enzyme. The spectra show a high level of similarity 
suggesting the overall fold of the protein has not been significantly altered by the amino acid 
substitutions. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17: CD spectrum of all MtuIPMS mutants using 0.2 mg/mL enzyme exchanged into double-
distilled water at pH 7.0. Wild-type = blue; A558I = red; A558V = green; V551L = orange; A567V = purple; 
I627A = yellow. 
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2.11 Thermal stability of variants 
The thermal stabilities of the MtuIPMS variants were examined to establish whether any major 
differences in stability in the presence of leucine, isoleucine and norvaline have occurred when 
compared to the wild-type enzyme under the same conditions. 
 
Figure 2.18: DSF data showing denaturation temperatures of MtuIPMS wild-type and variants in the 
presence of 5 mM leucine, isoleucine and norvaline. The wild-type is shown in blue, A558I in red, A558V 
in green, V551L in purple, A567V in yellow and I627A in orange. Experiment was carried out with 20mM 
KCl, 3mM MgCl2 in 25 mM BTP buffer at pH 8.0. 
 
The MtuIPMS A558I variant was destabilised under all experimental conditions compared to the 
wild-type enzyme and all other variants. This protein also did not show any additional 
stabilisation in the presence of the tested ligands suggesting the ability of the A558I variant to 
bind these ligands has been severely attenuated. 
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The MtuIPMS A558V variant showed the same denaturation temperature (Tm) as the wild-type 
enzyme when no ligands were present showing this amino acid substitution has not led to a 
significant change in stability of the unbound enzyme. However, this variant shows a similar 
stabilisation trend to the wild-type enzyme in the presence of all three tested ligands but to a 
lesser degree. 
MtuIPMS V551L also showed the same Tm as the wild-type enzyme with no ligand present, 
however, in the presence of both leucine and isoleucine an increase in Tm was observed 
compared to the wild-type enzyme with these ligands, suggesting increased enzyme stability 
under these conditions. In the presence of 5 mM norvaline the same Tm was observed as the 
wild-type enzyme suggesting the amino acid substitution had not affected the stability of the 
protein in the presence of norvaline. 
MtuIPMS A567V showed increased stability across all tested conditions suggesting this amino 
acid substitution had an overall stabilising effect on the enzyme. Similar increases in Tm in 
response to the three amino acid ligands were observed as for the wild-type enzyme. 
The MtuIPMS I627A variant showed a slightly higher Tm than the wild-type enzyme, however, in 
the presence of leucine and isoleucine the same absolute level of enzyme stability was 
observed as for the wild-type enzyme, so overall less stability was gained by addition of these 
ligands than observed for the wild-type enzyme. Interestingly, no effect on enzyme stability was 
observed in the presence of norvaline. 
Table 2.4: Denaturation temperature for MtuIPMS wild-type and variants without ligand and in the 
presence of 5 mM leucine, isoleucine and norvaline. Results were obtained in 25 mM BTP buffer at pH 
8.0. 
                                        Denaturation Temperature ( ºC) 
Enzyme No ligand Leucine Isoleucine Norvaline 
MtuIPMS WT 47.6 ± 0.1 51.6 ± 0.1 49.6 ± 0.1 51.6 ± 0.1 
MtuIPMS A558I 45.3 ± 0.1 45.4 ± 0.1 44.9 ± 0.1 45.3 ± 0.1 
MtuIPMS A558V 47.6 ± 0.1 49.6 ± 0.1 47.7 ± 0.1 49.6 ± 0.1 
MtuIPMS V551L 47.6 ± 0.1 52.5 ± 0.1 51.4 ± 0.1 51.6 ± 0.1 
MtuIPMS A567V 49.6 ± 0.1 52.5 ± 0.1 51.5 ± 0.1 52.6 ± 0.1 
MtuIPMS I627A 48.6 ± 0.1 51.5 ± 0.1 49.5 ± 0.1 48.8 ± 0.1 
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2.12 Kinetic properties of variants 
Kinetic data was obtained for each variant to ensure no significant change in the catalytic 
activity of the variants had taken place due to the amino acid substitutions (Table 2.5). No 
significant differences in the kinetic parameters were observed between the variants and the 
wild-type enzyme. Km values obtained for α-KIV were between 4 and 10 µM. Km values obtained 
for AcCoA were between 40 and 72 µM. Turnover rates of between 3 and 4 s-1 were found for 
the wild-type and all variants.  
 
Table 2.5: Michaelis-Menten data obtained for the wild-type (WT) MtuIPMS and each variant. 
Conditions for obtaining α-KIV data: 300 µM AcCoA, 500 µM DTP, 3 mM MgCl2, 20 mM KCl. Conditions 
for obtaining AcCoA data: 400 µM α-KIV, 500 µM DTP, 3 mM MgCl2, 20 mM KCl. All data was obtained at 
pH 8.0 in 50 mM Tris-HCl buffer. Michaelis-Menten plots are shown in Appendix B. 
 
Enzyme α-KIV Km (µM) AcCoA Km (µM) kcat  (s
-1) 
MtuIPMS WT 8.4 ± 0.8 41 ± 3 3.6 ± 0.1 
MtuIPMS A558I 9.7 ± 1.0 72 ± 5 3.9 ± 0.1 
MtuIPMS I627A 4.2 ± 0.4 40 ± 3 3.2 ± 0.1 
MtuIPMS A567V 5.0 ± 0.4 56 ± 3 4.1 ± 0.1 
MtuIPMS V551L 9.1 ± 0.8 46 ± 3 3.6 ± 0.1 
MtuIPMS A558V 6.7 ± 0.6 53 ± 3 4.0 ± 0.1 
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2.13 Allosteric inhibition of variants 
Initial rate data 
Inhibition data with leucine, isoleucine and norvaline was obtained for each variant. Data 
shown is taken from the initial measured rate however, each variant also displayed allosteric 
slow-onset inhibition with all three tested inhibitors (Figures 2.22 and 2.23). 
 2.13.1 Leucine inhibition 
 
 
 
 
 
 
 
Figure 2.19: Response of wild-type and variant MtuIPMS to 0.5 mM (blue), 1 mM (red) and 5 mM 
(green) of leucine. Experimental conditions: 500 µM AcCoA, 400 µM α-KIV, 500 µM DTP, 20 mM KCl and 
3 mM MgCl2 in Tris-HCl buffer at pH 8.0. 
 
As noted previously the wild-type MtuIPMS displays maximal inhibition at 500 µM of leucine, 
and maintains the same level of inhibition when the leucine concentration is increased to 5 
mM. The MtuIPMS A558I variant displays a significant loss in sensitivity towards leucine; a 
concentration of 5 mM leucine was only able to reduce the remaining activity to 67 %. This 
decrease in sensitivity towards leucine was also observed for the MtuIPMS A558V variant 
suggesting this residue plays a very important role in the inhibition of the enzyme by leucine. 
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The MtuIPMS A558V variant only reaches approximately 86 % remaining activity at 5 mM of 
leucine making this the least sensitive variant to leucine created in this study. No significant 
differences between the wild-type enzyme and MtuIPMS V551L were observed at all leucine 
concentrations. The inhibition data of the MtuIPMS A567V variant was also similar to the data 
determined for the wild-type enzyme, except that at 500 µM leucine less inhibition was 
observed. However, interestingly, at 5 mM leucine greater inhibition was observed compared 
to the wild-type enzyme suggesting a different means of inhibition may be occurring such as 
ligand binding at another region of the protein. The MtuIPMS I627A variant displays very similar 
inhibition to the MtuIPMS A558I variant. 
2.13.2 Isoleucine inhibition
 
Figure 2.20: Response of wild-type and variant MtuIPMS to 1 mM (blue) and 5 mM (red) of isoleucine. 
Experimental conditions: 500 µM AcCoA, 400 µM α-KIV, 500 µM DTP, 20 mM KCl and 3 mM MgCl2 in 
Tris-HCl buffer at pH 8.0. 
 
There was no significant difference in inhibition observed between the wild-type MtuIPMS and 
any of the variants when assayed with 1 and 5 mM isoleucine. 
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2.13.3 Norvaline inhibition 
 
 
 
 
 
 
 
 
Figure 2.21: Response of wild-type and variant MtuIPMS to 1 mM (blue) and 5 mM (red) of norvaline. 
Experimental conditions: 500 µM AcCoA, 400 µM α-KIV, 500 µM DTP, 20 mM KCl and 3 mM MgCl2 in 
Tris-HCl buffer at pH 8.0. 
 
Wild-type MtuIPMS displays little inhibition at 1 mM of norvaline and is inhibited to 
approximately 45 % of the full enzyme activity at 5 mM norvaline. MtuIPMS A558I and A558V 
both display a similar lack of inhibition even at 5 mM norvaline. The MtuIPMS V551L variant 
displays similar inhibition to the wild-type enzyme but is slightly more inhibited than the wild-
type enzyme at both tested concentrations of norvaline. Interestingly the MtuIPMS A567V 
variant displays a huge increase in sensitivity towards norvaline suggesting it is possible to tune 
the amino acid selectivity from one ligand to another using only a single amino acid 
substitution. The A567V variant is inhibited to approximately 10 % of the uninhibited activity at 
1 mM norvaline and is further inhibited to approximately 6 % activity at 5 mM norvaline. The 
MtuIPMS I627A variant displays a lack of sensitivity towards norvaline and behaves similarly to 
the A558I and A558V variants. 
0
20
40
60
80
100
120
WT A558I A558V V551L A567V I627A
R
em
ai
n
in
g 
ac
ti
vi
ty
 (%
) 
55 
 
2.14 Observed slow-onset inhibition data 
In order to investigate the slow-onset allosteric inhibition characteristics of MtuIPMS, reaction 
rates were measured upon initiation of the reaction and two minutes after reaction initiation 
with 5 mM concentrations of each of the tested ligands. No slow-onset inhibition data was 
obtained with the MtuIPMS variants A558I, A558V or I627A as their lack of sensitivity towards 
the tested inhibitors meant that the available substrate was used too quickly to view if any 
slow-onset behaviour was occurring. 
2.14.1 MtuIPMS V551L observed slow-onset inhibition 
 
Figure 2.22: Observed slow-onset allosteric inhibition of MtuIPMS V551L with differing concentrations 
of inhibitors. Shown in blue are remaining activity percentages based upon the measurement of initial 
rates. Shown in red are the remaining activity percentages of rates measured 2 minutes after reaction 
initiation. Experimental conditions: 500 µM AcCoA, 400 µM α-KIV, 500 µM DTP, 20 mM KCl and 3 mM 
MgCl2 in Tris-HCl buffer at pH 8.0. 
 
The MtuIPMS V551L variant shows similar slow-onset nature to the wild-type enzyme except 
the difference in the remaining activity percentage with norvaline is not as great between the 
initial and steady state values. 
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2.14.2 MtuIPMS A567V observed slow-onset inhibition 
 
 
 
 
 
 
 
 
Figure 2.23: Observed slow-onset allosteric inhibition of MtuIPMS A567V with differing concentrations 
with tested inhibitors. Shown in blue are remaining activity percentages based upon initial rates 
measured. Shown in red are the remaining activity percentages of rates measured 2 minutes after 
reaction initiation. Experimental conditions: 500 µM AcCoA, 400 µM α-KIV, 500 µM DTP, 20 mM KCl and 
3 mM MgCl2 in Tris-HCl buffer at pH 8.0. 
 
The MtuIPMS A567V variant showed similar slow-onset characteristics to the other variants 
where 5 mM concentrations of leucine and norvaline produced almost identical inhibition data. 
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2.15 Summary of findings 
 
MtuIPMS variants were successfully created, expressed and purified by metal-affinity and size-
exclusion chromatography. Mass spectra showed each variant was of the expected size. CD 
spectra showed the variants had a similar folding profile to the wild-type suggesting there were 
no major structural changes due to the amino acid substitutions. 
Kinetic assays revealed the Michaelis-Menten kinetics of the wild-type enzyme and each 
generated variant. The enzyme activity of the variants in the absence of the tested inhibitors 
seemed unchanged with AcCoA Km values between 40 and 72 µM, α-KIV Km values between 5 
and 10 µM and turnover rates between 3 and 4 s-1. This kinetic data is similar to the kinetic data 
found for other α-IPMS enzymes.30,40 
It was found that the residues in the regulatory site play a vital role in the regulation of the 
enzyme where even one amino acid change can lead to drastic changes in the inhibition 
behaviour of the enzyme. No change in regulatory sensitivity towards isoleucine was observed 
for any of the variants, however the I627A, A558I and A558V variants displayed a greater 
relative sensitivity towards isoleucine than leucine due to the loss in leucine sensitivity. The 
A567V variant showed increased sensitivity to norvaline while maintaining similar sensitivity to 
leucine at the tested concentrations. 
Molecular modelling was carried out to examine the structure of MtuIPMS with norvaline and 
isoleucine-bound instead of leucine. The regulatory sites of MtuIPMS illustrating the positions 
of norvaline and isoleucine binding with respect to leucine can be used to help analyse the 
effects that the substitutions have had on the response of the inhibitors (Figures 2.24 and 2.25). 
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Figure 2.24: MtuIPMS with norvaline modelled in the leucine binding site. Norvaline is shown in orange, 
leucine is shown in yellow and surrounding residues are shown in blue. Residues substituted in this 
study are labeled in red. 
 
 
 
 
 
 
 
 
Figure 2.25: MtuIPMS with isoleucine modelled in the leucine binding site. Norvaline is shown in orange, 
leucine is shown in yellow and surrounding residues are shown in blue. Residues substituted in this 
study are labelled in red. 
A558 
Y554 
A567 
I627 
P625 N532 
A536 
D563 
L535 
V551 
A558 
P625 
D563 
V551 
I627 
A567 
Y554 
N532 
A536 
L535 
59 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.26: Location of mutated residues in MtuIPMS where leucine is shown in cyan, Val551 in orange, 
Ala558 in purple, Ala567 in green and Ile627 in yellow. 
 
The inhibition results from this study suggest the Ala558 and Ile627 residues in MtuIPMS play 
an important role in the binding of the natural inhibitor, leucine, and norvaline, as alteration of 
these residues to different amino acids with the same properties (non-polar amino acids) leads 
to insensitivity to inhibition. Interestingly, all changes made to these residues had no effect on 
the inhibition observed with isoleucine, introducing the possibility that the inhibition which is 
seen with isoleucine may be due to the ligand binding elsewhere on the protein scaffold 
inducing an inhibitory effect, although this is unlikely, and the modelling studies suggest that 
isoleucine can be accommodated at the leucine binding site. The lack in sensitivity of the 
Ala558 variants may be due to the increase in side chain length disrupting the binding of the 
inhibitors due to a decrease in available space within the regulatory pocket. Another possibility 
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of the lack in inhibition is the location of Ala558 in the protein. Ala558 is located at the terminal 
of the flexible β-strand which is thought to form a lid over the regulatory site (Figure 2.26). The 
increase in side chain length may force the afore-mentioned β-strand into a position where it 
blocks the tested inhibitors entering the regulatory site leading to a lack of inhibition. 
The lack of sensitivity of the I627A variant to all tested inhibitors may be associated with the 
shortening of the chain length increasing the available space within the regulatory pocket which 
may lead to a lack in hydrophobic interaction between the tested ligands and the regulatory 
residues. It is possible the increase in the size of the regulatory pocket may also allow water to 
enter the site making it unfavourable for binding of the inhibitors. 
Substitution of Val551 to leucine showed little change in the inhibition compared to the wild-
type enzyme with any of the tested inhibitors suggesting either this residue plays a minimal role 
in the formation of the regulatory pocket and inhibitor binding or that the slightly shorter 
leucine residue plays a similar role at this position as both of these residues are non-polar 
(Figures 2.24 – 2.26). 
The final residue examined, Ala567, displayed some interesting inhibitory characteristics. While 
the inhibition with isoleucine was comparable to the wild-type enzyme, a decrease in sensitivity 
was displayed towards leucine at lower concentrations. As the leucine concentration increased 
the maximal inhibition percentage of the enzyme was at a lower level than the wild-type 
enzyme. The most unexpected result was observed with norvaline where a high level of 
sensitivity was observed even at 1 mM norvaline showing that the substitution of one amino 
acid residue can tune the inhibitor selectivity towards another ligand. The effects of this 
substitution could be due to the side chain of norvaline being flexible. This flexability may allow 
it to adopt a stable conformation within the regulatory pocket despite the increase in side chain 
length due to the substitution of the Ala567 residue leading to possible occlusion of one side of 
the regulatory pocket (Figure 2.27). 
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Figure 2.27: Regulatory site of MtuIPMS showing the Ala567 residue exchanged to valine (green) with 
norvaline (blue) overlapped with leucine (cyan). Val551 is shown in orange, Ala558 in purple and Ile627 
in yellow. 
 
The wild-type MtuIPMS enzyme and the V551L and A567V variants displayed slow-onset 
inhibition with each of the tested inhibitors suggesting these residues do not play an important 
role in the slow-onset mechanism for the MtuIPMS enzyme.  
DSF revealed that the denaturation temperature of the wild-type and variants increased in the 
presence of the tested ligands leucine, isoleucine and norvaline at concentrations of 5 mM 
except for the A558I variant in which similar results for the denaturation temperature were 
found both in the presence and absence of ligand. The overall trend of increasing denaturation 
temperature in the presence of ligands suggests that upon binding these inhibitors the enzyme 
complex created is more stable than the unbound enzyme alone.  
Some comparisons can be drawn between the DSF data obtained and the inhibition data.  The 
MtuIPMS A558I, which experienced little change in stability in the presence and absence of 
inhibitor, showed little inhibition with any of the tested inhibitors as would be expected. The 
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A558V variant however, shows little inhibition by the tested ligands but still displays a 
substantial increase in denaturation temperature with both leucine and isoleucine (though not 
as much as for the wild-type enzyme) and shows no stabilisation by isoleucine despite being 
inhibited by this ligand. The V551L variant displays similar responses to the wild-type enzyme 
for both the inhibition and DSF data once again illustrating the unlikelihood for this residue 
playing a major role in the inhibition of the enzyme. The A567V variant shows an overall 
increase in absolute denaturation temperature both in the presence and absence of ligands; 
however, the relative denaturation temperatures in the presence of the inhibitors are less than 
for the wild-type enzyme. The inhibition data suggests significantly increased norvaline affinity, 
so it was expected that an increase in stabilisation by norvaline relative to the wild-type enzyme 
might be observed. These discrepancies were perhaps due to the use of 5 mM ligand 
concentrations in the DSF assays whereas 1 mM may have been more discriminatory and show 
more about the nature of the stabilisation of each ligand. The I627A variant displayed an 
increase in denaturation temperature in the absence of ligands. The same absolute 
denaturation temperature as the wild-type enzyme was obtained with leucine and isoleucine 
meaning the relative increase in temperature due to the addition of ligands was not as great. 
No stabilisation effect was observed in the presence of norvaline.  
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Chapter 3 
Effects of amino acid substitutions made to the 
α-IPMS from Neisseria meningitidis on the 
regulatory signal transfer throughout the 
enzyme 
 
3.1 Overview 
 
The goal of this research was to see if single amino acid changes could be made to the α-IPMS 
from N. meningitidis (NmeIPMS) at positions located away from the regulatory and active sites 
of the enzyme which would lead to an alteration in the inhibition by leucine due to the 
disruption in the signal transfer from the regulatory domain to the catalytic domain. 
These NmeIPMS variants were characterised via enzyme kinetic studies, protein mass 
spectrometry, differential scanning fluorimetry and circular dichroism. Enzyme kinetic studies 
included obtaining Michaelis-Menten constants and inhibition data with leucine for each 
variant generated. Protein mass spectrometry was implemented to ensure the purified protein 
was of the correct mass. Differential scanning fluorimetry was used to determine the melting 
temperatures of the wild-type and each variant in the presence of different inhibitors and in 
the absence of inhibitor. Finally circular dichroism was used to ensure the chosen variants did 
not significantly alter the secondary structure of the enzyme via comparison to the wild-type 
protein. 
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3.2 Design of the NmeIPMS variants 
The NmeIPMS variants were made based upon molecular dynamic simulations performed by 
Dr. Wanting Jiao and Chloe Thompson on the BlueFern supercomputer at the University of 
Canterbury. 
3.3 NmeIPMS variant justification 
As there is no current full length crystal structure solved for NmeIPMS, analysis of the enzyme 
was done using a homology model generated by Dr. Wanting Jiao based on the crystal structure 
of MtuIPMS (PDB code 3FIG). 
3.3.1 NmeIPMS homology model 
 
 
 
 
 
 
 
Figure 3.1: Homology model of NmeIPMS showing one monomer in grey. The other monomer is 
separated into the catalytic domain (purple), subdomain I (red), subdomain II (yellow) and the 
regulatory domain (blue). Leucine is shown in cyan.  
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The NmeIPMS homology model (Figure 3.1) was created based upon sequence alignment with 
MtuIPMS and the structural alignment with the truncated NmeIPMS structure.24 As for 
MtuIPMS, the model is homodimeric and comprised of a catalytic and regulatory domain 
separated by subdomains I and II. Structurally the NmeIPMS enzyme is very similar to MtuIPMS 
despite being 127 amino acid residues shorter. This extra length of MtuIPMS was in part, the 
reason why the NmeIPMS homology model was built. A significant proportion of the structure 
of MtuIPMS is unresolved in the crystal structures, indicating that these regions show 
significant conformational flexibility. Sequence alignments of α-IPMS enzymes show that these 
regions are not present in α-IPMS proteins from other species, therefore the NmeIPMS model 
was built as a more representative structure of the majority of α-IPMS enzymes. 
Molecular dynamic studies were then carried out comparing the dynamic trajectories and 
movement of residues between leucine-bound and ligand-free forms of the enzyme to predict 
residues that may play an important role in allosteric function. Residues located in the catalytic 
domain of NmeIPMS showed little movement between bound and unbound forms, the 
subdomains I and II however, which are thought to play a significant role in the signal transfer 
through the protein, display the greatest flexibility.  
Interestingly, the leucine-bound and ligand-free forms of the enzyme display a clear difference 
in orientation and motion in subdomain I, II and the regulatory domain. In the ligand free 
system, subdomain I is disordered and orientated into the opening of the catalytic barrel. When 
leucine is bound, subdomain I displays significantly less movement due to hydrogen bonding 
between key residues (Figure 3.3-3.5) and other important interactions within the protein 
scaffold. The increase in rigidity of the structure holds subdomain I over the top of the catalytic 
barrel for the majority of the trajectory. Subdomain II adopts significantly different orientations 
between the leucine-bound and ligand-free forms. When no leucine is bound, the α-helices 
adopt a conformation in which subunit II is parallel to the β-sheets of the regulatory domain. 
When leucine binds, the orientation of the α-helices changes propping up the regulatory 
domain (Figure 3.2). The regulatory domain undergoes a large shift from the leucine-bound to 
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ligand-free form, which likely disrupts bonds involved in the interface connection between the 
regulatory domain and subdomain II preventing regulation of the enzyme. 
Preliminary results from molecular dynamics simulations (112.6 ns for the ligand free system 
and 119 ns for the leucine-bound system) suggest that a number of the residues which are 
involved in structurally important hydrogen bonds and salt bridges display a conformational 
shift between leucine-bound and ligand-free forms of the enzyme suggesting they may play a 
vital role in the inhibitory signal transfer from the leucine binding site to the catalytic site. 
Detailed below are some of these important residues which have been altered to investigate 
the inhibitory signal transfer mechanism.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Homology model of the NmeIPMS average ligand-free system (left) and average leucine-
bound system (right) displaying significant differences in positions of the subunits. Catalytic domain 
(purple), subdomain I (red), subdomain II (yellow) and the regulatory domain (blue). Leucine is shown in 
cyan. 
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The importance of asymmetry between the two monomers in the structure (as modelled from 
the MtuIPMS structure)33 was displayed when looking at which residues on each monomer that 
were forming important hydrogen bonds, as without this asymmetry these residues would be 
located in a position which they would not be able to interact. It is possible that for MtuIPMS 
and other variants that this asymmetry is an important part of the regulatory system. 
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3.3.2 NmeIPMS E466A 
In the leucine-bound form of NmeIPMS, Glu466 located on the β-sheet of the regulatory 
domain forms a hydrogen bond with Ser352 located on the flexible loop of subdomain II below 
the regulatory site (Figure 3.3). This interaction keeps subdomain II stacked in an upright 
position (Figure 3.2) below the regulatory domain. The average trajectory for the ligand-free 
form shows a hydrogen bond occupancy of 1.45 % which increases to 63.4 % for the average 
trajectory in the leucine-bound form. This implies the interaction may play an important role in 
communication of leucine binding to subdomain II. Upon binding leucine, the dynamics 
simulations indicate that subdomain II also loses its upright orientation. In the ligand-free 
model a slight rotation of subdomain II is permitted after the loss of this anchoring (as the 
S353-E466 hydrogen bond is disrupted) and subdomain II becomes more parallel to the β-
sheets of the regulatory domain (Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Demonstration of the change in distance between residues E466 and S352 in the average 
ligand-free (left) and leucine-bound (right) form of NmeIPMS. In the ligand-free model a hydrogen bond 
distance of 9.6 Å was observed compared to a distance of 4.1 Å in the leucine-bound model. 
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3.3.3 NmeIPMS E353A 
Glu353 interacts strongly with both Ser468 and Arg470 via hydrogen bonding in the leucine-
bound form (Figure 3.4). Differences in hydrogen bond occupancy for the Glu352-Ser468 
interaction were determined as 21.9 % in the leucine-bound form of NmeIPMS and 2.6 % in the 
ligand-free form calculated over the entire simulation. The Glu353-Arg470 occupancy decreases 
from 40.2 % in the leucine-bound form to 0.1 % in the ligand-free form. Both Ser468 and 
Arg470 are located on the lower β-sheets of the regulatory domain which are able to interact 
with Glu353 which is located on the loop of subdomain I.  
 
 
 
 
 
  
 
 
 
Figure 3.4: Demonstration of interactions between E353, S468 and R470 in the average ligand-free (left) 
and leucine-bound (right) forms of NmeIPMS. Hydrogen bond distances in ligand-free form: E353-S468 = 
7.4 Å, E353-R470 = 6.6 Å. Hydrogen bond distances in leucine-bound form: E353-S468 = 3.8 Å, E353-
R470 = 3.0 Å. 
 
R470 
E353 
E353 
R470 
  
71 
 
3.3.4 NmeIPMS R310A 
Arg310 is located in subdomain I on a flexible linker region thought to form a ‘capped lid’ over 
the catalytic domain that prevents substrate entering the active site (Figure 3.5). This 
interaction between subdomains is not observed in the leucine unbound structure. This is 
supported by hydrogen bond occupancy between Arg310 and Glu319 decreasing from 43.8 % in 
the leucine-bound form to 5.0 % in the ligand-free form. Arg310-Glu314 hydrogen bond 
occupancy also drops from 51.2 % in the leucine-bound form to 12.2 % in the ligand-free form. 
Hydrogen bond occupancies were calculated over the entire simulation of the leucine-bound 
and ligand-free form.  
 
 
 
 
 
 
Figure 3.5: Demonstration of interactions between R310, E314 and E319 in the ligand-free form (left) 
and leucine-bound form (right) of NmeIPMS. Hydrogen bond distances in ligand-free form: R310-E314 = 
11.3 Å, R310-E319 = 14.0 Å. Hydrogen bond distances in leucine-bound form: R310-E314 = 2.6 Å, R310-
E319 = 2.9 Å. 
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3.4 NmeIPMS variant generation using PCR 
NmeIPMS variants were created via mutation of the wild-type NmeIPMS gene using PCR. The 
NmeIPMS gene was found inserted in a pET-151 plasmid.24 The wild-type gene contained 
coding for a TEV protease cleavage site attached to the 5’ end of the gene. The plasmid also 
included coding for an N-terminal polyhistidine tag to make the protein easier to purify after 
expression, a T7 promoter region binding a lac operon to enable over-expression of the protein 
of interest after addition of IPTG and an ampicillin resistance gene to allow for growth selection 
of cells which contain the gene of interest. The TEV protease cleavage site was included so that 
the His-tag could be removed after IMAC had been performed. The plasmid was located in E. 
coli One Shot TOP10 cells and was obtained using plasmid isolation. The purified plasmid was 
then run on an agarose gel to ensure the obtained plasmid was the expected size of 5000 bp. 
 
 
 
 
 
 
 
 
 
Figure 3.6: Agarose gel showing isolated plasmid containing the wild-type NmeIPMS gene. Marker sizes 
are shown in base pairs. Marker weights between 3000 and 12000 bp increase 100 bp per band. 
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After the plasmid bearing the wild-type gene was isolated, PCR was used to introduce the 
mutations of choice into the wild-type NmeIPMS gene. The PCR products were then subjected 
to Dpn1 in order to digest the parental methylated DNA leaving the copies of the gene which 
contain the mutation intact. The PCR products were then analysed on an agarose gel, however 
no bands were observed. Based upon the site-directed mutagenesis kit guide, the PCR products 
were transformed into E. coli One Shot TOP10 cells which were grown on LB/agar plates 
containing ampicillin as a selection marker. The plasmids were then obtained from the cells and 
sequenced. The sequences were then compared to the wild-type sequence to ensure the 
correct mutations had been made in the gene. Plasmids which contained the correct gene 
mutation were then transformed into E. coli BL21(DE3)Star cells for protein expression. 
 
3.5 Expression of protein 
The expression of the NmeIPMS wild-type enzymes and variants was carried out as described in 
the materials and methods section (Chapter 5). After expression cell pellets were stored at          
-80°C until required. Proteolysis can occur in the cell lysate during purification steps. To 
minimise this lysis to immobilised metal affinity chromatography (IMAC) steps were performed 
in close succession and protease inhibitor was added to the lysate. 
Cell lysis was performed using sonication. A large proportion of the over-expressed protein was 
found in the supernatant at the expected molecular mass of 60 kDa for the His-tagged protein. 
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3.6 Purification 
The wild-type NmeIPMS and variants were purified in the same manner as MtuIPMS (described 
in Chapter 2) except instead of using a Ni2+ containing IMAC column, a Talon® column 
containing Co2+ was used. This procedure involved IMAC chromatography of the crude protein 
after which TEV protease was added to remove the His-tag. The protein sample was then run 
back through the Talon® column to separate the clean untagged protein from the tag and 
uncleaved protein. SEC was used as a final cleaning step to ensure protein was of high-purity. 
This purification procedure resulted in protein of high purity for all characterisation assays. The 
addition of DTT was performed prior to addition of TEV protease in order to reduce disulfide 
bonds that may form between the proteins allowing for better access to the TEV cleavage site. 
The dilution with SEC buffer is performed to reduce imidazole concentration in preparation for 
TEV protease activity. 
This purification procedure usually led to 5-10 mg of protein for a 1 L cell culture in lysogeny 
broth (LB). 
 
3.6.1 Immobilised metal affinity chromatography 
The first step used in the purification procedure of NmeIPMS was IMAC. A Talon® column 
charged with Co2+ ions was used to separate NmeIPMS from background E. coli proteins via the 
N-terminal His-tag. Protein which bound to the column was eluted with 150 mM imidazole. 
 
3.6.2 Desalting 
Protein is eluted from the IMAC column in a buffer containing a high concentration of 
imidazole. For this reason prior to the addition of TEV protease the pooled fractions were 
diluted with SEC buffer to ensure the imidazole did not interfere with protein stability or TEV 
protease efficiency. 
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3.6.3 TEV protease cleavage 
Once the desalting step had been completed the protein was digested with TEV protease 
overnight at 4°C to remove the N-terminal His-tag. Removal of the His-tag was carried out to 
minimize the chances of the tag interfering with the characterisation of NmeIPMS. 
The His-tag added 33 amino acid residues to the N-terminus of NmeIPMS including the 6 
histidine residues used to bind to the IMAC column and the TEV protease recognition sequence. 
After digestion, 6 residues (GIDPFT) are left attached to the N-terminus of NmeIPMS. 
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Figure 3.7: Residues located at the N-terminal of NmeIPMS. Red shows the His-tag, green shows the TEV 
protease recognition sequence and cyan shows the extra residues introduced to the N-terminal of the 
NmeIPMS after TEV protease activity. 
 
After the incubation with TEV was complete the solution was run back through the Talon® Co2+ 
column. The untagged protein did not bind to the column and was eluted in the flow-through, 
while the cleaved tag and background E. coli protein that bound to the column in the last step 
bound to the column. 
 
3.6.4 Size-exclusion chromatography 
The last step in the purification protocol is SEC, which elutes MtuIPMS in one peak and 
aggregated proteins in an earlier peak. The mass of the purified protein is of the expected 
molecular mass of 56 kDa. The gel of the wild-type and variants is shown in figure 3.8. 
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Figure 3.8: SDS-PAGE showing purified NmeIPMS wild-type and variants. Lane 1, wild-type; lane 2, 
R310A variant; lane 3, E353A variant; lane 4, E466A variant and lane 5 shows the marker ladder. Marker 
weights are shown in kDa. 
 
3.7 Mass spectrometry 
All NmeIPMS enzymes were measured using MS to ensure all enzymes were of the expected 
mass calculated from amino acid sequence using ProtParam (Table 3.1).47 
 
Table 3.1: Expected and calculated masses of each NmeIPMS variant. Calculated masses obtained using 
mass spectrometry. 
Enzyme Expected mass (Da) Calculated mass (Da) 
NmePMS WT 56027.4 56026.7 
NmeIPMS R310A 55942.3 55940.8 
NmeIPMS E535A 55969.4 55967.7 
NmeIPMS E466A 55969.4 55969.3 
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3.8 NmeIPMS wild-type 
3.8.1 Physical characterisation 
This section details the examination of the wild-type enzyme. This work took place for later 
comparison with the NmeIPMS variants. 
3.8.2 Secondary structure analysis 
A CD spectrum was obtained for NmeIPMS wild-type enzyme to ensure the protein was folded 
properly and to use as a comparison for the NmeIPMS variants to ensure no major structural 
change had taken place. 
 
Figure 3.9: CD spectra of the wild-type NmeIPMS in double-distilled water at pH 7.0. The protein 
concentration was 0.2 mg/mL. 
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The shape of the CD spectrum of NmeIPMS wild-type suggests proper folding of the protein. 
This presence of secondary structure suggests it is suitable for further characterisation. 
 
3.8.3 Thermal stability 
The wild-type NmeIPMS was subjected to DSF to investigate its thermal denaturation 
temperatures in the absence of ligand and in the presence of 1 and 5 mM leucine. 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Example of a DSF curve for the wild-type NmeIPMS enzyme with 5 mM leucine present 
where in blue is the relative fluorescence unit (RFU) and shown in red is the negative derivative of the 
RFU. The melting temperature is recorded as the steepest part of the RFU trace and the minimum on 
the negative derivative. The experiment was carried out in 25 mM BTP buffer supplemented with 20 
mM MgCl2 and 20 mM KCl at pH 7.5. 
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The DSF results showed the wild-type NmeIPMS (Figure 3.11) had a denaturation temperature 
of 43.6 ± 0.1 °C with no leucine present. When leucine was added at concentration of 1 mM the 
denaturation temperature increased to 45.2 ± 0.1 °C which is a small but significant difference 
in the thermal stability of the enzyme. Upon addition of 5 mM leucine the denaturation 
temperature increased further to 46.5 ± 0.1 °C. These results suggest that leucine binding to 
the wild-type enzyme results in a more thermally stable protein. 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Effects on Tm of NmeIPMS wild-type in the presence 1 and 5 mM leucine in 25 mM BTP 
buffer (pH 7.5). 
 
 
3.8.4 Kinetic characterisation 
The activity of NmeIPMS was studied first by finding the apparent Michaelis-Menten constants 
for the two substrates (α-KIV and AcCoA). Once these results had been obtained inhibition 
studies were performed to examine the response of the wild-type NmeIPMS and variants to 
varying leucine concentrations. 
All assays were carried out using a DTP coupled assay which was monitored at 324 nm.  
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3.8.5 Michaelis-Menten kinetics 
Apparent Km and turnover values were found for the wild-type NmeIPMS at 25 °C and pH 7.5 
(Table 3.3). While obtaining the AcCoA Km the α-KIV concentration was held at 500 µM. While 
obtaining the α-KIV Km the AcCoA concentration was held at 500 µM. A Km value of 37.3 ± 3.4 
µM was obtained for AcCoA and a Km of 31.9 ± 1.5 µM for α-KIV. A kcat value of 8.9 ± 0.1 s
-1 was 
obtained. 
Michaelis-Menten curves obtained are shown in figure 3.12. Michaelis-Menten data can be 
viewed in table 3.3. 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.12: Michaelis-Menten plots obtained for wild-type NmeIPMS showing the apparent AcCoA (left) 
and α-KIV (right) Km. A Km of 37.3 ± 3.4 µM was obtained for AcCoA and a Km of 31.9  ± 1.5 µM was 
obtained for α-KIV. A kcat value of 8.9 ± 0.1 s
-1 was obtained. Each assay contained: 20 mM MgCl2, 20 mM 
KCl and 500 µM DTP in 50 mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer at 
pH 7.5. 
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3.8.6 Allosteric inhibition by leucine 
The inhibition of wild-type NmeIPMS by leucine (Figure 3.13) was analysed by varying the 
concentration of leucine present in the cuvette while holding the substrate and metal ion 
concentrations at the same conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Inhibition of wild-type NmeIPMS with varying leucine concentrations. Inhibition data was 
determined with 500 µM AcCoA, 550 µM α-KIV, 20 mM MgCl2, 20 mM KCl and 500 µM DTP in 50 mM 
HEPES buffer at pH 7.5. Amount of enzyme used in each assay was 1.6 µg. 
 
The inhibition data of wild-type NmeIPMS at different leucine concentrations showed the 
enzyme was maximally inhibited at a level of 22 ± 4 % activity. An approximate half-maximal 
effective concentration (EC50) value of 5 µM leucine was obtained showing the natural 
inhibitor of NmeIPMS, leucine, is a potent inhibitor as expected.  
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3.9 Analysis of NmeIPMS variants 
3.9.1 Structure analysis 
CD spectra of NmeIPMS variants were overlaid with the wild-type spectrum to ensure the 
variants were folded properly and no major perturbations had occurred due to the amino acid 
substitutions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: CD spectrums of NmeIPMS wild-type and variants overlaid. The wild-type is shown in black, 
R310A in red, E353A in blue and E466A in purple.  
 
The high degree of similarity between the NmeIPMS enzymes spectra suggests no large 
differences in the structure of variants had occurred due to the changes in sequence. 
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3.9.2 Thermal stability with leucine 
The denaturation temperature of each of the variants was determined with no leucine, 1 mM 
leucine and 5 mM leucine for comparison with the wild-type NmeIPMS enzyme (Figure 3.15). 
 
Figure 3.15: Denaturation temperature of wild-type NmeIPMS and variants obtained using DSF. Blue 
shows denaturation temperatures with no leucine, red with 1 mM leucine and green with 5 mM leucine. 
Experiments were carried out in the presence of 20 mM MgCl2 and KCl in 25 mM BTP buffer at pH 7.5. 
 
Results from DSF studies show an overall trend in all of the enzymes where in the presence of 
leucine an increase in denaturation temperature occurs (Table 3.2), suggesting the binding of 
leucine leads to a more thermally stable enzyme-inhibitor complex. The R310A variant displays 
a slightly higher denaturation temperature than the wild-type enzyme with no leucine present 
suggesting that this amino acid mutation has led to an increase in thermal stability of the 
protein. The increase in the thermal stability of this variant with 1 mM leucine is comparable to 
the rise observed in the wild-type enzyme, however, no further increase in denaturation 
temperature was observed from 1 to 5 mM.  The E353A variant showed a similar response to 
leucine as the wild-type enzyme except all denaturation temperatures were approximately 2 °C 
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lower than for the wild-type enzyme. The E466A variant showed some interesting results. The 
denaturation temperature with no leucine present increased dramatically from 43.6 to 50.1 °C. 
This suggests that this amino acid substitution provides thermal stability to the enzyme. 
Substantial increases in denaturation temperature were observed in the presence of both 1 and 
5 mM leucine further demonstrating the change in thermal stability this substitution has made, 
and with 5 mM leucine a denaturation temperature of 65.1 °C is observed.  
Table 3.2: Denaturation temperature for NmeIPMS wild-type and variants without ligand and in the 
presence of 1 and 5 mM leucine. Results were obtained with 20 mM MgCl2 and 20 mM KCl in 25 mM 
BTP buffer at pH 7.5. 
 Denaturation temperature (ºC) 
Enzyme No ligand 1 mM leucine 5 mM leucine 
NmeIPMS WT 43.6 ± 0.1 45.2 ± 0.1 46.5 ± 0.1 
NmeIPMS R310A 45.3 ± 0.1 46.0 ± 0.1 45.9 ± 0.1 
NmeIPMS E353A 41.6 ± 0.1 43.2 ± 0.1 43.9 ± 0.1 
NmeIPMS E466A 50.1 ± 0.1 61.9 ± 0.5 65.1 ± 0.5 
 
 
3.9.3 Kinetic properties 
Michaelis-Menten constants were obtained for each variant to observe if any significant 
changes in the catalytic activity of the variants had taken place due to the amino acid 
substitutions (Table 3.3). Michaelis-Menten values were found using different co-substrate 
concentrations for each variant due to the differences in their kinetic behaviour. 
Table 3.3: Michaelis-Menten constants for wild-type NmeIPMS and variants. 
Enzyme α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
NmeIPMS WT 32  ± 2 37 ± 3 13 ± 1 
NmeIPMS R310A ND* 750 ± 260 5.1 ± 0.7 
NmeIPMS E353A 29 ± 2 19 ± 1 11.6 ±0.1 
NmeIPMS E466A 29 ± 3 79 ± 3 9.3 ± 0.1 
 
 
* ND means not determined.  
**Details of experimental conditions are provided in chapter 5. 
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Table 3.4: kcat/Km values for wild-type NmeIPMS and variants where ND means not determined. 
Enzyme α-KIV kcat/Km (µM
-1s-1) AcCoA kcat/Km (µM
-1s-1) 
NmeIPMS WT 0.41 ± 0.06 0.35 ± 0.06 
NmeIPMS R310A ND* 0.007 ± 0.003 
NmeIPMS E353A 0.40 ± 0.03 0.61 ± 0.04 
NmeIPMS E466A 0.32 ± 0.04 0.12 ± 0.01 
 
* ND means not determined. 
 
The complete Michaelis-Menten data set for the NmeIPMS variant R310A was not obtained due 
to the need for high concentrations of AcCoA to determine the apparent α-KIV Km. Initial results 
did reveal a much higher AcCoA Km value than the wild-type enzyme of around 750 µM and a 
low kcat/Km value of 0.007 µM
-1s-1. 
The other NmeIPMS variants display similar Km values for α-KIV suggesting these amino acid 
substitutions do not play an important role in the binding of α-KIV. Similarly the AcCoA Km 
values obtained for the variants are similar to the wild-type enzyme with the E353A variant 
displaying a slightly lower Km value of 19 ± 1 µM and the R310A variant showing a higher Km 
than the wild-type with a value of 79 ± 3 µM. Each of the variants displays a small decrease in 
kcat showing these amino acid substitutions have had a detrimental effect on the rate of 
substrate turnover.  
The kcat/Km values for α-KIV show that little effect on the enzymes’ catalytic performances 
results from these amino acid substitutions. More significant differences are observed when 
looking at the kcat/Km values for AcCoA. The NmeIPMS E353A variant displays a significant 
increase in catalytic efficiency of 0.61 ± 0.04 µM-1s-1 compared with the wild-type value of 0.35 
± 0.06 µM-1s-1. Alternatively a decrease in the catalytic efficiency is observed with the NmeIPMS 
E466A variant where a decrease in the kcat/Km value from 0.35 ± 0.06 µM
-1s-1 to 0.12 ± 0.01 µM-
1s-1 was observed.  
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3.10 Inhibition by leucine of NmeIPMS variants 
3.10.1 NmeIPMS R310A 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Inhibition of NmeIPMS R310A with increasing leucine concentrations. Inhibition data found 
with 500 µM AcCoA, 550 µM α-KIV, 20 mM MgCl2, 20 mM KCl and 500 µM DTP in 50 mM HEPES buffer 
at pH 7.5. Amount of enzyme used in each assay was 8 µg. 
 
Despite this NmeIPMS variant displaying a significant decrease in catalytic activity compared to 
the wild-type enzyme, the substrates were held at the same concentrations as the other 
NmeIPMS enzymes as a limited amount of AcCoA was available (therefore AcCoA was not 
saturating). An approximate EC50 value of 2 µM leucine was obtained, indicating that this 
mutant is slightly more sensitive to leucine than the wild-type enzyme. The enzyme reaches a 
maximum inhibition level of 12 ± 4 % remaining activity compared to the 22 ± 4 % remaining 
activity of the maximally inhibited wild-type enzyme. 
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3.10.2 NmeIPMS E353A 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Inhibition of NmeIPMS E353A with increasing leucine concentrations. Inhibition data found 
with 500 µM AcCoA, 550 µM α-KIV, 20 mM MgCl2, 20 mM KCl and 500 µM DTP in 50 mM HEPES buffer 
at pH 7.5. Amount of enzyme used in each assay was 1.6 µg. 
 
An approximate EC50 value of 8 µM leucine is obtained. This is slightly higher than the value for 
the wild-type enzyme suggesting that this variant is slightly less sensitive to leucine compared 
to the wild-type enzyme. The enzyme reaches a maximum inhibition level of 28 ± 6 % remaining 
activity compared to the 22 ± 4 % remaining activity of the maximally inhibited wild-type. 
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3.10.3 NmeIPMS E466A 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Inhibition of NmeIPMS E466A with increasing leucine concentrations. Inhibition data found 
with 500 µM AcCoA, 550 µM α-KIV, 20 mM MgCl2, 20 mM KCl and 500 µM DTP in 50 mM HEPES buffer 
at pH 7.5. Amount of enzyme used in each assay was 1.6 µg. 
 
An approximate EC50 value of 0.5 µM leucine is obtained. This value is much lower than that of 
the wild-type enzyme and shows a major change in sensitivity towards leucine associated with 
this substitution. The enzyme reaches a maximum inhibition level of 13 ± 6 % remaining activity 
compared to the 22 ± 4 % remaining activity of the maximally inhibited wild-type enzyme. 
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3.11 Summary of findings 
 
The NmeIPMS variants were successfully created, expressed and purified using IMAC and SEC. 
The variants created were of the expected size as shown by MS. The CD spectra showed that 
each of the variants were folded in a similar conformation as the wild-type enzyme, suggesting 
no major structural changes had occurred due to the amino acid changes. 
Michaelis-Menten kinetics showed a difference in the kinetic activities of the variants where 
the apparent Km of AcCoA was slightly altered in the E353A and E466A variants and significantly 
increased in the R310A variant. Measured apparent Km values for α-KIV were similar to that of 
the wild-type enzyme. Each variant also displayed a small decrease in kcat displaying the 
importance that individual amino acids play in the function of the protein as a whole. The 
kcat/Km values were once again similar for α-KIV but varied significantly for AcCoA. This data 
suggests that AcCoA binding and catalysis is highly susceptible to alteration by changes in the 
overall conformation of the enzyme due to changes in hydrogen bond formation. AcCoA is a 
large substrate and is located peripherally to the catalytic barrel (Figure 3.19). The size of AcCoA 
and its binding location may make it more susceptible to changes in the relative position of the 
catalytic barrel and subdomain I, whereas, the relatively small α-KIV which displays similar α-
KIV binding across the variants, is largely unaffected by relative subdomain movements. 
Inhibition data found with the natural inhibitor leucine showed similar sensitivity towards 
leucine for the R310A and E353A variants although small differences were observed.  This data 
suggests these residues alone play a minor role in the overall transfer of regulatory signal. 
Interestingly these variants displayed changes to the maximal level of inhibition observed when 
compared to the wild-type enzyme suggesting the changes in conformation of the enzymes due 
to these salt-bridges being disturbed can alter the extent of which the enzyme can be inhibited. 
The lack of influence of a single mutation could possibly be due to multiple regulatory signal 
transfer pathways operating within the enzyme so that the alteration of one of these pathways 
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alone does not have a substantial effect. These favoured signal transfer pathways could lead to 
the different levels of maximal inhibition observed. 
The E466A variant displayed a significant increase in sensitivity towards leucine which was 
unexpected as this substitution was designed to disrupt hydrogen bond formation with Ser352 
thus mimicking the uninhibited state therefore it was expected to see a drop in sensitivity of 
the enzyme towards leucine. This unexpected change in leucine sensitivity could be due to the 
enzyme adopting a different conformation, leading to increased leucine inhibition via utilisation 
of other regulatory signal transfer pathways in the enzyme. This possibility is supported by the 
significant increase in the denaturation temperature observed with this variant in the presence 
of increasing levels of leucine (Table 3.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: NmeIPMS homology model with AcCoA bound (red) based upon the crystal structure of 
LiCMS13 (PDB code 3BLI) showing the large area AcCoA interacts with when binding to the enzyme. 
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Denaturation temperatures found using DSF showed a general trend of increasing the melting 
temperature as the concentration of leucine increased for the NmeIPMS wild-type and variants. 
The R310A variant displayed a lesser increase in protein stability upon addition of leucine than 
the wild-type enzyme and variants suggesting this amino acid substitution may have had a large 
effect on the ability of the enzyme to adopt a stable conformation upon leucine binding, as 
would be expected with the disruption of the hydrogen bond usually formed at this position. 
The E353A variant displayed similar denaturation temperatures to the wild-type suggesting the 
hydrogen bonds formed upon leucine binding do not play a significant role in the stability of the 
enzyme. The E466A variant showed a large increase in denaturation temperature of almost 
20 °C was found with 5 mM leucine. Once again this variant displayed unexpected results as it 
was thought that the disruption of the hydrogen bond to Ser352 would be expected to result in 
a decrease in denaturation temperature due to the enzyme becoming more flexible. This raises 
the possibility that upon disruption of the Glu466-Ser352 hydrogen bond, the enzyme is free to 
explore different hydrogen bonding contacts which are more stabilising.  
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Chapter 4 
Summary of thesis and future directions 
 
The aim of this research is to increase the understanding of the allosteric inhibition of α-IPMS 
and probe the effect of single amino acid substitutions on inhibitor selectivity. To study this, α-
IPMS enzymes from M. tuberculosis23,24 and N. meningitidis24 were altered using site-directed 
mutagenesis and characterised using a variety of methods and conditions to probe the effects 
on inhibitor selectivity and regulatory signal transfer. 
α-IPMS enzymes from M. tuberculosis and N. meningitidis were expressed, purified and 
characterised using MS, DSF and kinetic assays. α-IPMS enzymes from these organisms were 
chosen due to their pathogenic nature, introducing the possibility that these enzymes may be 
viable drug targets. The wild-type enzymes were found to have similar catalytic activity and 
regulation to α-IPMS enzymes previously studied,23,30,40 with Km values for the substrates α-KIV 
and AcCoA in the micromolar range, kcat values between 3 and 15 s
-1 and inhibition constants 
also in the low micromolar range.23,30,39,40 
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4.1 Changes to the regulatory pocket of MtuIPMS can have a 
large effect on the inhibitor selectivity and sensitivity of the 
enzyme 
 
MtuIPMS enzymes studied are homodimeric comprising of a catalytic (β/α)8-barrel domain, two 
subdomains and a regulatory domain comprised of a distinct (βββα)2 fold (Figure 1.7). The two 
subdomains separate the catalytic and regulatory domains and are thought to play a vital role 
in the transfer of the regulatory signal from the regulatory domain to the catalytic domain upon 
binding of the natural inhibitor, leucine. CMS is an enzyme which shares distinct similarities to 
α-IPMS, such as the overall structure, the reaction catalysed and the feedback regulation by a 
similar molecule, isoleucine (Figure 1.14-1.15).13,35  
Recently, studies on the regulatory site of LiCMS by Zhang et al13 where variants (based on 
docking studies) were created via site-directed mutagenesis to attempt to change the inhibitor 
selectivity of LiCMS from isoleucine to leucine. Results from this study showed that the V468A 
variant of LiCMS displayed significantly increased leucine sensitivity. However this variant also 
displayed increased inhibition to the natural inhibitor isoleucine. Other mutation in this study 
included Y430L, L451V, Y454A and I458A which all displayed a decrease in the catalytic 
efficiency of the enzyme and a decrease in sensitivity to isoleucine. The Y454A variant also 
displayed an increase in sensitivity towards leucine, but to a lesser extent than the V468A 
variant. The comparative locations of these substituted residues with MtuIPMS residues can be 
viewed in figure 2.2. In light of these studies, it was proposed that a change in inhibitor 
selectivity could be achieved by alteration to hydrophobic residues in the regulatory pocket of 
MtuIPMS via site-directed mutagenesis, to resemble the regulatory pocket in CMS, changing 
the inhibitor selectivity from leucine to isoleucine.  
Variants of MtuIPMS in which key amino acids which line the hydrophobic pocket responsible 
for the interaction with the hydrophobic side chain of leucine were created to explore the 
effects on inhibitor sensitivity and enzyme regulation. These variants displayed similar catalytic 
activities to the wild-type enzymes; however, inhibition by leucine and norvaline was 
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significantly altered. The variants displayed similar inhibition properties with isoleucine 
suggesting alteration of the binding for this allosteric effector may require multiple regulatory 
site residue changes.  
Interestingly, a single amino acid change of Ala567 to a valine was able to tune the inhibitor 
selectivity from leucine to norvaline showing it is indeed possible to tune inhibitor selectivity 
with a single amino acid substitution.  
Many of the variants did display a decrease in sensitivity towards leucine while maintaining 
their sensitivity towards isoleucine, meaning that the relative inhibitor selectivity of the 
enzymes had indeed been altered from leucine to isoleucine. However, combinations of 
changes may well be required to effectively switch inhibitor sensitivity. 
 
4.2 Disruption of hydrogen bonding contacts can have large 
consequences on enzyme activity, regulation and stability 
 
NmeIPMS was used to explore the mechanism of regulatory signal transfer between the 
catalytic and regulatory domain. In α-IPMS the catalytic and regulatory ligand binding sites are a 
large distance apart relative to the overall size of the enzyme, and they are separated by 
subdomains I and II, which are thought to mediate regulatory signal transfer upon binding of 
the inhibitor, leucine. Comparisons of the ligand-free and leucine-bound MtuIPMS crystal 
structures reveal little structural change on ligand binding.33 However, recent preliminary 
molecular dynamic simulations of NmeIPMS shows considerably more flexibility and structural 
differences in the enzyme between the ligand-free and leucine-bound model than previously 
thought and raises the possibility that a conformational shift may occur between the 
asymmetric monomer units. Relatively short molecular dynamic studies also displayed a 
difference in hydrogen bond occupancies calculated over ligand-free and leucine-bound 
trajectories of key residues located in the subdomains (Figure 3.3-3.5). This led to the work 
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carried out as part of this thesis to substitute these key residues and examine the effects on 
catalytic ability, regulation and stability of the enzyme. 
Single amino acid substituted variants of NmeIPMS were created via site-directed mutagenesis 
to explore the transfer of the regulatory signal from the regulatory domain to the catalytic 
domain upon binding of the natural inhibitor leucine. Significant differences in catalytic 
activities were observed, with kcat/Km values for AcCoA of between 0.007 ± 0.003 and 0.61 ± 
0.04 µM-1s-1, while maintaining relatively similar kcat/Km values for the substrate α-KIV. The 
E466A variant displays a significant increase in inhibition by leucine compared to the wild-type 
enzyme (with an EC50 value of 0.5 µM compared to 5 µM in the wild-type) while the other 
variants show similar inhibitory characteristics to the wild-type enzyme with the exception that 
the maximal level of inhibition is altered in the variants. From this data it is observed that the 
Glu466 residue appears to play a significant role in the regulation and thermal stability of the 
enzyme.  
Mutation of Glu466 to an alanine resulted in an enzyme with significantly higher denaturation 
temperatures in the presence and absence of leucine. The R310 residue appears to play a 
significant role in binding AcCoA as data suggests at least a ten-fold increase in the apparent Km 
of AcCoA. When the E353 residue was substituted for alanine a two-fold increase in the 
apparent Km for AcCoA of the enzyme was observed suggesting it may also play a role in the 
binding of AcCoA. 
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4.3 Future Experiments 
 
4.3.1 What is the effect upon inhibitor selectivity of double and 
triple amino acid substituted variants of MtuIPMS? 
 
Single amino acid substitutions in MtuIPMS produced significant differences in enzyme 
selectivity and sensitivity with leucine and norvaline. However, no increase in the sensitivity 
towards isoleucine was observed. The creation of double and triple amino acid substituted 
variants of MtuIPMS may lead to more drastic changes in the inhibitor selectivity compared to 
what was observed in the work carried out in this thesis.  
For example, the A567V variant displayed significantly increased sensitivity to norvaline while 
maintaining leucine sensitivity. The A558V variant displayed a decrease in regulation with all 
tested inhibitors. It is possible that creating a double amino acid substituted variant with these 
changes would lead to an enzyme that displays high sensitivity towards norvaline and loses 
sensitivity toward leucine. Another viable change would be the further increase in side chain 
length of Val551 and adding a bulky substituent such as glutamic acid to select for isoleucine, 
which lacks the C4 methyl group of leucine, while shortening the side chain of Ile627 to an 
alanine to make room for the C3 methyl group of isoleucine (Figure 4.1). Results from these 
experiments would increase the understanding of how the regulatory binding site residues 
interact with the inhibitors and lead to potential new studies into the regulation of α-IPMS. 
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Figure 4.1: Left: Regulatory site of MtuIPMS with key residues labelled. Residues to be mutated are 
labelled in red. Right: Regulatory site of MtuIPMS with the mutations I627A and V551L labelled in red 
and coloured in grey. Leucine is shown in green and isoleucine is shown in orange. 
 
4.3.2 Does removing multiple possible regulatory signal transfer 
pathways reduce enzyme regulation in NmeIPMS? 
 
Single amino acid substitutions to disrupt hydrogen bond interactions deemed as significant by 
molecular dynamic modelling had a large effect of the binding affinity for AcCoA and enzyme 
regulation with leucine. It would be interesting to see the effects on the regulation, catalytic 
activity and stabilisation of NmeIPMS variants with multiple hydrogen bond disruptions run 
over longer simulation trajectories (up to µs in length). This may help elucidate the mechanism 
of the regulatory signal transfer throughout the enzyme and establish if a monomer 
conformation interconversion through a symmetrical for of the enzyme occurs. 
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4.4 Concluding Remarks 
 
The understanding of the inhibitor binding selectivity, sensitivity and signal transfer is vital to 
the overall understanding of enzymatic function. MtuIPMS and NmeIPMS have provided an 
insight into these mechanisms. Further studies are required to gain a full understanding of 
these functions. 
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Chapter 5 
Materials and Methods 
 
5.1 General methods 
5.1.1 Water 
All buffers and solutions used in this research were made using water treated with a Millipore 
Milli-Q system prior to use. 
5.1.2 Determination of pH 
The pH of relevant solutions was determined using either the Denver Instruments UB-10 Ultra-
Basic pH meter or Mettler Toledo SevenCompact pH meter. Solutions were made acidic via the 
addition of HCl and basic by addition of NaOH. 
5.1.3 Protein structure viewing and images 
Structural representations of proteins were generated using the program “PyMOL™” Molecular 
Graphics System, version 1.5.0.3. (Schrödinger, LLC). 
5.1.4 Sequence alignments 
All sequence alignments were performed using the Clustal Omega tool 
(www.ebi.ac.uk/Tools/msa/clustalo/). 
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5.2 Site-directed mutagenesis  
5.2.1 Primers 
Primers were designed using PrimerX (www.bioinformatics.org/primerx) and synthesised by 
GeneWorks. Primers were stored at 100 µM in TE buffer (10mM Tris-HCl, 0.1mM EDTA). A full 
list of primers used can be found in table 5.1. 
 
Table 5.1: Primers used to generate variants in MtuIPMS and NmeIPMS. Mutated bases are shown in 
bold. 
Enzyme PCR primer 5’-3’ 
MtuIPMS A558I Forward: GACTACTACGAGCACATTATGAGCGCCGGCGAC 
Reverse:  GTCGCCGGCGCTCATAATGTGCTCGTAGTAGTC 
MtuIPMS A558V Forward: CTACTACGAGCACGTGATGAGCGCCGGCG 
Reverse:  CGCCGGCGCTCATCACGTGCTCGTAGTAG 
MtuIPMS V551L Forward: GTTTGACGTGGCCCTGCTGGACTACTAC 
Reverse:  GTAGTAGTCCAGCAGGGCCACGTCAAAC 
MtuIPMS A567V Forward: GACGACGCTCAGGTGGCCGCGTATGTG 
Reverse:  CACATACGCGGCCACCTGAGCGTCGTC 
MtuIPMS I627A Forward: CGCACCGTCAGCGACCACCGCGTCGCTGCGCGC 
Reverse:  GCGCGCAGCGACGCGGTGGTCGCTGACGGTGCG 
NmeIPMS R310A Forward: GACGGGGTGCTGAAACACGCGGAAACTTACGAGATTATG 
Reverse:  CATATTCTCGTAAGTTTCCGCGTGTTTCAGCACCCCGTC 
NmeIPMS E353A Forward: GTTGGAAAGCGCGGAGGCACTGAAC 
Reverse:  GTTCAGTGCCTCCGCGCTTTCCAAC 
NmeIPMS E466A Forward: GAAAGCCAAGGCGCGACCAGCGTCCGTC 
Reverse:  GACGGACGCTGGTCGCGCCTTGGCTTTC 
 
5.2.2 PCR equipment 
PCR reactions were performed using a Veriti® 96-well Thermal Cycler (Applied Biosystems). 
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5.2.3 Mutagenesis of MtuIPMS variants 
Amino acid-substituted MtuIPMS variants A558I, A558V, A567V, V551L and I627A were 
generated by creating mutations in the plasmid pProExHTa-LeuA. Mutagenesis was performed 
using either a QuikChange XL II Site-directed Mutagenesis Kit, QuikChange Lightning Site-
directed Mutagenesis Kit or a PfuUltra High-Fidelity DNA polymerase (Agilent Technologies©), 
using cycling protocols and a reaction volume of 50µL. reaction components used as 
recommended by each manufacturer. 
After PCR the template DNA was digested using a High-Fidelity Dpn1 restriction enzyme 
(Stratagene) for 5 min at 37°C. 
5.2.4 Mutagenesis of NmeIPMS variants 
NmeIPMS variants R310A, E353A and E466A were generated by creating mutations in the 
plasmid pET-151. Mutagenesis was performed using a QuikChange Lightning Site-directed 
Mutagenesis Kit containing PfuUltra High-Fidelity DNA polymerase, using cycling protocols and 
a reaction volume of 50 µL. Reaction components used as recommended by the manufacturer. 
After PCR the template DNA was digested using a High-Fidelity Dpn1 restriction enzyme 
(Stratagene) for 5 min at 37°C. 
5.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed using either self-poured 1% agarose gels or pre-cast 
E-Gel® 1.2% (w/v) agarose gels (Invitrogen). 
E-Gel® agarose gels were used following the manufacturers guidelines. Samples were loaded 
directly to the gel with no dye. Gels were run using an E-Gel® iBase™ Safe Imager™. 
Self-poured agarose gels were made by heating 0.4 g agarose is 40 mL tris-acetate-EDTA (TAE) 
buffer until dissolved. The solution was then cooled to ~50°C and 4 µL of SYBR Safe® DNA stain 
was added. The solution was then poured into a mould. Samples to be run on self-poured gels 
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were mixed with a 6x loading dye. Electrophoresis was run at 85 V for 60 min with TAE for 
running buffer using a Mini-Sub® Cell GT (Bio-Rad). 
Gels were viewed and photographed under UV light using a Molecular Imager® Gel Doc™ XR 
(Bio-Rad). 
TAE buffer: 60mM Tris-HCl, 1mM EDTA, 20mM acetic acid. 
Sample loading dye (6x): 60mM Tris-HCl, 60mM EDTA, 0.2% (w/v) orange G, 0.05% (w/v) xylene 
cyanol ff, 60% (v/v) glycerol. 
5.2.6 Chemical transformation 
Transformations were performed by thawing 50 µL or 100 µL samples of chemically competent 
cells on ice for 15 min then adding 2-5 µL plasmid (30-200 ng/µL). Samples were then incubated 
for a further 20 min on ice followed by a heat-shock step for 45 s at 42°C. Samples were then 
place back on ice for 2-4 min after which 250 µL super optimal broth (SOC) medium was added 
to the cells. The cells were then grown at 37°C for 1 h with shaking. After growth, 20-200µL of 
the cells was spread on LB-agar plates containing the appropriate antibiotics. These plates were 
then incubated at 37°C for 12-18 h. 
SOC medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgSO4 and 20mM glucose. 
5.2.7 Plasmid preparation and purification 
Plasmids were extracted and purified from 5 mL cell cultures grown at 37°C overnight 
(containing the appropriate antibiotics) of OneShot TOP10 or XL1Blue cell lines. Cells were 
harvested and then plasmids were extracted using a Roche High Pure Plasmid Isolation Kit. The 
plasmid extraction and purification was carried out following the kit manual. 
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5.2.8 DNA sequencing 
DNA sequencing was carried out by Canterbury Sequencing on an ABI3100 Genetic Analyzer 
(Applied Systems Inc.) using a procedure based on Sanger chain-determination protocol. 
Double-stranded plasmid samples were prepared as 6µL aliquots of 20-80 ng/µL plasmid per 
sequencing run. Sequencing primers were provided at 3.2µM. A list of sequencing primers used 
can be found in table 5.2. 
 
Table 5.2: Sequencing primers used throughout this study. The pProEx primers were used to sequence 
MtuPMS and T7 primers were used for NmeIPMS sequencing. 
Sequencing primer Sequence of primer 
pProEx Forward AGCGGATAACAATTTCACACA 
pProEx Reverse ATCTGTATCAGGCTGAAAATC 
T7 Forward TAATACGACTCACTATAGGG 
T7 Reverse GCTAGTTATTGCTCAGCGG 
 
5.3 Cell cultures 
5.3.1 Escherichia coli cell lines 
E. coli OneShot TOP10 cell lines were used for plasmid propagation, and E. coli BL21(DE3)Star 
for protein expression.  
5.3.2 Glycerol stocks 
All E. coli strains created during this study were stored at -80°C as 1.2 mL samples containing 20% v/v 
glycerol. Cells were grown for 12-16 h before addition of glycerol and flash-freezing. 
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5.3.3 Antibiotics 
All plasmids used in this study carry resistance to ampicillin. Ampicillin was included in all cell cultures at 
a concentration of 0.1 mg/mL. Antibiotics were stored at -80°C at 1000x the desired final concentration 
dissolved in water. 
5.3.4 LB media 
Cell cultures were grown in liquid LB broth which was autoclaved before use. The appropriate 
antibiotic was added before use. 
LB-agar was stored at room temperature and melted via microwave before use. After melting 
the solution was allowed to cool to around 50 °C then the appropriate antibiotic was added for 
selection. The solution was then poured into round petri dishes. 
Liquid LB: 20 g/L Lennox-L broth base 
LB-agar: 20 g/L Lennox-L broth base, 15 g/L agar 
5.3.5 Protein expression 
All α-IPMS enzymes were expressed and purified using similar protocols. A typical expression 
consisted of two batches of 1 L LB medium containing the appropriate antibiotic inoculated by a 
small scale pre-growth which was in turn inoculated by a scraping of frozen glycerol stock. The 
1 L cultures were grown at 37 °C until an OD600 of 0.5-0.7 AU was reached at which time IPTG 
was added to a concentration of 0.25 mM. Cultures were then grown overnight at 23 °C. 
5.3.6 Cell harvesting 
Cell cultures were harvested in 1 L flasks by centrifugation at 14,000 g for 10 min at 4 °C. Small 
cultures of less than 5 mL were harvested in 1.6 mL micro-centrifuge tubes at 17,000 g for 5 
min. 
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5.4 Purification 
5.4.1 Cell lysis 
Before lysis, cells were resuspended in 15 mL equilibration buffer. Lysis was performed using an 
Omni-Ruptor 4000 Ultrasonic Homogenizer (Omni International) or a detergent based method 
using Bugbuster®.  
Sonication was performed on ice. Typical lysis consisted of 4 repeats of 70 % power at 35 Hz for 
5 min. The sample temperature was check after each repeat to ensure over-heating did not 
occur. 
Small scale growths were lysed using Bugbuster® following their provided protocol. 
After lysis the solution was centrifuged at 44,000 g for 45 min to separate the soluble fraction 
from the insoluble. Chromatography was performed without delay to minimise proteolysis. 
5.4.2 Chromatography equipment 
All chromatography was performed using either a GE Healthcare AKTApurifier™ 10 or a Bio-Rad 
BioLogic DuoFlow. All buffers used were filtered using a 0.2 µm prior to being injected into a 50 
mL Superloop™ (GE Healthcare). Protein elution was monitored at 260 nm and 280 nm and 
peaks at these wavelengths were analysed for protein of interest using SDS-PAGE gels. 
Chromatography was performed at 4°C for overnight protocols and room temperature for 
protocols under 3 hours. 
5.4.3 Immobilised metal affinity chromatography 
All protein purified in this thesis underwent of two IMAC steps. The first of these 
chromatography steps separated the His-tagged protein from soluble E. coli background 
proteins. The second step separated the untagged protein from the His-tag and TEV protease 
after tag cleavage. 
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IMAC was performed using either a 5 mL Histrap® column (GE healthcare) or a 5 mL Talon® 
Metal Affinity column (GE Healthcare). In both protocols the columns were equilibrated using 5 
column volumes (CV) of equilibration buffer. Elution was performed via a 50:50 equilibration: 
elution buffer gradient over 10 CV for MtuIPMS. For NmeIPMS a single step elution buffer 
change was used to elute bound protein for a length of 6 CV. After use all columns were 
washed through for 5 to 10 CV of low-salt buffer and stored in ethanol. 
Histrap equilibration buffer: 50 mM KPO4, 25 mM Imidazole, 250 mM NaCl at pH 7.5 
Histrap elution buffer: 50 mM KPO4, 400 mM Imidazole, 250 mM NaCl at pH 7.5 
Talon equilibration buffer: 50 mM KPO4, 300 mM KCl, 10 mM Imidazole at pH 8.0 
Talon elution buffer: 50 mM KPO4, 300 mM KCl, 150 mM Imidazole at pH 8.0 
5.4.4 TEV protease treatment 
To cleave the His-tag from the protein of interest protein from the first IMAC step was diluted 
ten-fold in SEC buffer containing no imidazole. TEV protease was then added to the protein 
containing solution and incubated at 4 °C overnight. This reaction also contained 1 mM DTT to 
reduced disulfide bonds. 1 mg of TEV protease was added to each sample. 
5.4.5 Size-exclusion chromatography 
The final purification stage of all proteins was performed using a Sephacryl® S-200 26/60 HiPrep 
column (GE Healthcare). The column was equilibrated with 1 column volume (CV) of SEC buffer 
before protein injection. The protein was then eluted with 1 CV SEC buffer and stored back in 
ethanol. 
MtuIPMS SEC buffer: 50 mM KPO4, 250 mM NaCl at pH 7.5 
NmeIPMS SEC buffer: 50 mM BTP at pH 7.0 
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5.4.6 Concentration of protein samples 
All protein samples were concentrated at 4 °C using a 10000 Da molecular weight cut-off 
centrifugal concentrator (GE Healthcare or Millipore). 
5.4.7 Determination of protein concentration 
The concentration of protein containing solutions were determined using a Nanodrop ND-1000 
spectrophotometer which measured the absorbtion at 280 nm. Protein concentration was then 
calculated using the Beer-Lambert Law and calculated extinction coefficients from Protparam 
(http://web.expasy.org/protparam/). 
5.4.8 Buffer exchange 
Exchanging buffers for protein solutions was done via successive concentration and dilution 
with desired buffer using a 10000 Da molecular weight cut-off centrifugal concentrator (GE 
Healthcare or Millipore) at 4 °C. 
5.4.9 Protein storage 
Purified protein was stored at -80 °C in 100 µL aliquots at 1-10 mg/mL. All aliquots were flash-
frozen using liquid nitrogen prior to storage. 
 
 
 
 
 
110 
 
5.5 Protein characterisation 
5.5.1 Protein parameters 
Protein parameters were calculated from sequence data using the Protparam tool 
(http://web.expasy.org/protparam/). All sequences included the additional residues GA (for 
MtuIPMS enzymes) and GIDPFT (for NmeIPMS enzymes) which are added to the N-terminal.  
5.5.2 Polyacrylamide gel electrophoresis 
SDS-PAGE was performed using either NuPAGE® 10 % Bis-Tris 12-well pre-cast gels (Invitrogen) 
or Bolt® 12% Bis-Tris 12-well gels. NuPAGE® gels were run in NuPAGE® MES SDS running buffer 
(Invitrogen). Bolt® gels were run in Bolt® MES SDS running buffer. Samples were mixed with 4x 
sample buffer and DTT then boiled for 5 min. 
Protein molecular weight standards were separated on the gel along with the protein samples. 
The protein marker used was Novex® Sharp Pre-Stained Protein Standards (Invitrogen). 
Gels were viewed by staining with a solution of 1 % Coomassie brilliant blue R-250, 40 % 
methanol and 10 % glacial acetic acid. Gels were then destained using a solution of 40 % 
methanol and 10 % glacial acetic acid. Both staining and destaining steps were gels were heated 
in the microwave with the appropriate solution. Gels were left on shaker for 15 min to stain and 
1 hour to destain. 
Gels were viewed and photographed using a Molecular Imager Gel Doc XR (Bio-Rad). 
5.5.3 Circular dichroism spectrometry 
CD spectra measurements were performed using a JASCO J-815 Spectropolarimeter. 
Wavelength scans were carried out in double-distilled water (pH 7.0) between wavelengths 
180-240 nm, with 0.5 data pitch, 1 seconds response and at 1 mm bandwidth at room 
temperature. Samples were prepared at an enzyme concentration of 0.2 mg/mL. 
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5.5.4 Mass spectrometry 
Protein masses were measured using a Bruker maXis 3G. 
5.5.6 Differential scanning fluorimetry 
DSF was performed using a Bio-Rad iCycler iQ5™ Multicolour Real-Time PCR Detection System. 
25 µL samples were prepared in a 96-well plate as follows: 20 µL BTP buffer (pH 7.5 for 
NmeIPMS or 8.0 for MtuIPMS) including ligands, 1 µL 250x SYPRO Orange dye and 4 µL of 
protein at 1 mg/mL. Ligand concentrations displayed in relevant chapters. 
The 96-well plated was sealed and subjected to a thermal melt program from 20 to 95 °C in 0.2 
°C increments holding each step for 20 s. Each sample was measured in triplicate and compared 
to a control containing everything but protein. 
5.6 Activity assays 
5.6.1 Kinetic assay equipment 
All kinetic assays were performed using a Varian Cary 100 UV-visible spectrophotometer using 
stoppered quartz cuvettes with a pathlength of 1 cm or 0.2 cm. 
Reaction rates were measured by calculating a least-squares fit of rate data in Cary WinUV 
Kinetic Application (Version 3, Varian). 
5.6.2 4-4’-Dithiodipyridine-coupled assays at 324 nm 
All activity assays were performed via a coupled assay using DTP to detect the formation of the 
CoA product at 324 nm at 25 °C (ε = 1.98 x 104 M-1cm-1) based on the method of de Carvalho et 
al.30 Reaction mixtures are described in the relevant chapter. 
All kinetic measurements were performed in duplicate or triplicate with errors typically under 
10 %. 
112 
 
5.6.3 Substrate concentration determination 
The concentrations of the solutions of substrates AcCoA and α-KIV were determined using DTP-
coupled assay at 324 nm.  Limiting amounts of substrate to be measured were added to the 
assay cuvette while the other substrate was held at excess concentration. The change in 
absorbance (ΔAbs) was measured in triplicate. A sample containing no substrates was used to 
measure the change in absorbance due to the increase in enzyme (ΔAbsenz). The corrected 
change in absorbance was then calculated as ΔAbs - ΔAbsenz. The corrected absorbance was 
then converted to the concentration of the limiting substrate using the Beer-Lambert Law with 
an extinction coefficient of 1.98 x 104 M-1cm-1. 
5.6.4 Michaelis-Menten kinetics 
Assays to determine apparent Km and kcat values for all enzymes used the DTP-coupled assay at 
324 nm. Apparent Km values were determined using SigmaPlot 11.0 by fitting to the Michaelis-
Menten equation. 
All Michaelis-Menten data was obtained using volumes of 1 mL in 1 cm pathlength cuvettes. 
5.6.5 MtuIPMS wild-type and variant Michaelis-Menten conditions 
All MtuIPMS Km values were found under the same conditions of  500 µM DTP, 3 mM MgCl2 and 
20 mM KCl. While obtaining apparent Km values for AcCoA, α-KIV was held at 400 µM. While 
obtaining apparent Km values for α-KIV, AcCoA was held at 500 µM. Assays were carried out in 
50 mM Tris-HCl buffer at pH 8.0. 
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5.6.6 NmeIPMS wild-type and variant Michaelis-Menten conditions 
NmeIPMS wild-type 
The wild-type NmeIPMS apparent AcCoA Km was found under the following conditions: 500 µM 
α-KIV, 500 µM DTP, 20 mM MgCl2 and 20 mM KCl in 50 mM HEPES buffer at pH 7.5. The 
apparent α-KIV Km was found under the following conditions: 190 µM AcCoA, 500 µM DTP, 20 
mM MgCl2 and 20 mM KCl in 50 mM HEPES buffer at pH 7.5.  
NmeIPMS R310A 
NmeIPMS R310A parameters were unable to be determined due to running out of the substrate 
AcCoA before an accurate value was obtained. Results did however show the catalytic activity 
of this variant was significantly impaired with an estimated apparent AcCoA Km of 750 µM. This 
was found under the following conditions: 500 µM α-KIV, 500 µM DTP, 20 mM MgCl2 and 20 
mM KCl in 50 mM HEPES buffer at pH 7.5.  
NmeIPMS E353A  
The apparent AcCoA Km for NmeIPMS E353A was found under the following conditions: 450 µM 
α-KIV, 500 µM DTP, 20 mM MgCl2 and 20 mM KCl in 50 mM HEPES buffer at pH 7.5. The 
apparent α-KIV Km was found under the following conditions: 150 µM AcCoA, 500 µM DTP, 20 
mM MgCl2 and 20 mM KCl in 50 mM HEPES buffer at pH 7.5.  
NmeIPMS E466A  
The apparent AcCoA Km for NmeIPMS E353A was found under the following conditions: 450 µM 
α-KIV, 500 µM DTP, 20 mM MgCl2 and 20 mM KCl in 50 mM HEPES buffer at pH 7.5. The 
apparent α-KIV Km for NmeIPMS E353A was found under the following conditions: 450 µM α-
KIV, 500 µM DTP, 20 mM MgCl2 and 20 mM KCl in 50 mM HEPES buffer at pH 7.5.  
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5.6.7 Inhibition assays 
All inhibition data obtained was carried out using the DTP-coupled assay in 250 µL cuvettes with 
a pathlength of 0.2 cm. Inhibition data was plotted and analysed using SigmaPlot 11.0 or 
Microsoft Excel 2010. 
MtuIPMS inhibition with L-leucine, L-isoleucine and L-norvaline was examined in this thesis in 
the relevant chapter. Concentrations up to 5 mM of each of the inhibitors was tested. 
Rates of time-dependant inhibition effects of MtuIPMS were measured for times up to two 
minutes. 
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Appendix A 
Multiple sequence alignments 
The following sequence alignments were performed using Clustal Omega. The sequence 
alignments were used in determination of MtuIPMS variants. 
MtuIPMS and LiCMS sequence alignment 
 
 
MTUIPMS      MTTSESPDAYTE----SFGAHTIVKPAGPPRVGQPSWNPQRASSMPVN--RYRPFAEEVE 54 
LICMS        ------------------------------------------------------------ 0 
 
MTUIPMS      PIRLRNRTWP-DRVIDRAPLWCAVDLRDGNQALIDPMSPARKRRMFDL-LVRMGYKEIEV 112 
LICMS        -----------MTKVETRLEILDVTLRDGEQTRGVSFSTSEKLNIAKFLLQKLNVDRVEI 49 
                                      **** *      *   *       *        *  
 
MTUIPMS      GFPSASQTDFDFVREIIEQGAIPDD---VTIQVLTQCRPE--LIERTFQACSGA-PRAIV 166 
LICMS        ASARVSKGELETVQKIMEWAATEQLTERIEILGFVDGNK-------TVDWIKDS-GAKVL 101 
                  *         * *  *         *               *                     
 
MTUIPMS      HFYNSTSILQRRVVFRANRAEVQAIATDGARKCVEQAAKYPG-TQWRFEYSPESY---TG 222 
LICMS        NLLTKGSLHHLEKQLGKTPKEFFTDVSFVIEYAIKS----GL----KINVYLEDWSNGFR 153 
                                 *                               *        
 
MTUIPMS      TELEYAKQVCDAVGEVIAPTPERPIIFNLPATVEMTTPNVYADSIEWMSRNLANRESVIL 282 
LICMS        NSPDYVKSLVEHLSKE------HIERIFLPDTLGVLSPEETFQGVDSLIQKYP---DIHF 204 
                 * *                     ** *                         
 
MTUIPMS      SLHPHNDRGTAVAAAELGFAAGADRIEGCLFGNGERTGNVCLVTLGLNLFSRGV------ 336 
LICMS        EFHGHNDYDLSVANSLQAIRAGVKGLHASINGLGERAGNTPLEALVTTIHDKSNS----- 259 
               * ***    **       **         * *** **  *  *                
 
MTUIPMS      ---------DPQIDFSNIDEIRRTVEYCNQLPVHERHPYGGDLVYTAFSGSHQDAINKGL 387 
LICMS        ---------KTNINEIAITEASRLVEVFSGKRISANRPIVGEDVFTQTAGVHADGDKKG- 309 
                              *    * **           *  *  ***  **** *   *   
 
MTUIPMS      DAMKLDADAAD-------CDVDDMLWQVPYLPIDPRDVGRTYEA-VIRVNSQSGKGGVAY 439 
LICMS        --------------------------NLYANPILPERFGRK-RS--YALGKLAGKASISE 340 
                                            ** *   **             **      
 
MTUIPMS      IMKTDHGLSLPRRLQIEFSQVIQKIAEGTAGEGGEVSPKEM-WDAFAEEYLAPVRP---- 494 
LICMS        NVKQ-LGMVLSD---VVLQKVLERVIE-LGDQNKLVTPEDL-PFIIADVSGRTGEK---- 390 
                                 *              * *        *              
 
MTUIPMS      ----------LE-----RIR-QHVDAADDDGG-T--------TSITATVKIN-------- 521 
LICMS        -----------------VLTIKSCNIHSGIGIRP-----------HAQIEL-----EY-Q 416 
                                                           *              
 
MTUIPMS      GVETEISGSGNGPLAAFVHALAD-VGF------DVAVLDYYEHAMSA--GDD-AQAAAYV 571 
LICMS        GKIHKEISEGDGGYDAFMNALTKITNRL--GISIPKLIDYEVRIPPG--GKTDALVETRI 472 
             *          *   **  **                 **             *              
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MTUIPMS      EASVTIASPAQPGEAGRHASDPVTIASPAQPGEAGRHASDPVTSKTVWGVGIAPSITTAS 631 
LICMS        TWNKS---------------------------------LDLEEDQTFKTMGVHPDQTVAA 499 
                                                    *     *    *  *  * *        
 
MTUIPMS      LRAVVSAVNRAAR----------------------------------------------- 644 
LICMS        VHATEKMLNQILQPWQI------------------------------------------- 516 
 
 
  
 
 
α-IPMS multiple sequence alignment  
 
 
 
CUR      -----MSNTDSFISAPAQIQTPNGEIPADQPAWNKQRNSQMPNRRYLPFFEEVDHITLPD 55 
CJK      ----------------------------------------MPHVRYQPFFEEVEEITLPD 20 
CDI      ----------------------------------------MAVNRYQPFHVEVENIDLPD 20 
CEF      ----------------------------------------MPVKRYLPFEVEVEDITLPD 20 
SEN      MSIPPEP----QTPISNRVRKPSRPAPADQQPWNPQLGSSMPFHRYRPFHELVEDVSLPD 56 
MLE      ----------------------------------------MPVFRYRPFAKEVEPIRLVD 20 
MTU      MTTSESPDAYTESFGAHTIVKPAGPPRVGQPSWNPQRASSMPVNRYRPFAEEVEPIRLRN 60 
RHA      ----MSP-ADAFTSGTRTITPPSKPAPSDQPEWNTQKNSSMPTFRYRSFSEEVEPVSLPD 55 
MSM      MNTPDIS-SDAFST-GRTITPPSGAPHPGQPAWNTQRGSSMPVSRYRSFADEVEKISLPD 58 
SAQ      ------------------MAHPAVTPDAETDPIARQQPSRMPYHRYQPYQQQF-RTDLPD 41 
LXX      ----------------------------------------MPIHKYRPFHEQI-AVDLPD 19 
KRA      -------------------------------MQNTQTPSPMPFGKYTPFQDQI-RVELPD 28 
RSA      -------------------------------MRNAQKPSGMPVHRYLPFHEQI-EVELPD 28 
AAU      -------------------------------MRNAQKPSGMPIHRYLPFQDQI-TVEVPD 28 
ART      -------------------------------MRNAQKPSGMPVHRYMPFQDQI-TVELPD 28 
                                                 *   :*  :   .    : : 
 
 
 
CUR      RTWPDKVIDRAPQWCAVDLRDGNQALIDPMSPERKRRMFDMLVEMGYKEIEVGFPSASQT 115 
CJK      RTWPDKVIDRAPQWCAVDLRDGNQALIDPMSPERKRRMFELLVDMGYKEIEVGFPSASQT 80 
CDI      RTWPQKRITKAPQWCAVDLRDGNQALIDPMSPERKRRMFNLLVNMGYKEIEVGFPSASQT 80 
CEF      RTWPDKKITQAPQWCAVDLRDGNQALIDPMSPERKRRMFELLVKMGFKEIEVGFPSASQT 80 
SEN      RTWPDNRITRAPLWCAVDLRDGNQALIDPMSPARKRRMFDLLVRMGFKEIEVGFPAASQT 116 
MLE      RTWPDRVIDCAPLWCAVDLRDGNQALIDPMSPICKRRMFDLLVRMGYKEIEVGFPSASQT 80 
MTU      RTWPDRVIDRAPLWCAVDLRDGNQALIDPMSPARKRRMFDLLVRMGYKEIEVGFPSASQT 120 
RHA      RSWPDKVIDRAPQWCAVDLRDGNQALIDPMSPARKRRMFELLVRMGYKEIEVGFPSASQT 115 
MSM      RTWPDKVIETAPMWCAVDLRDGNQALIDPMSPQRKRRMFDLLVRMGYKEIEVGFPSASQT 118 
SAQ      RSWPNRRVETAPRWCAVDLRDGNQALIDPMSPERKRRMFQLLVQLGYKEIEVGFPSASQS 101 
LXX      RTWPAKRIAVAPRWCAVDLRDGNQALIDPMSPERKRIMFDLLVRMGYKEIEVGFPSASQT 79 
KRA      RTWPTRTITKAPRWCAVDLRDGNQALIDPMNSERKLRMFTLLVQMGYKDIEVGFPSASQT 88 
RSA      RTWPTKRITTAPRWCAVDLRDGNQALIDPMSPARKLKMFELLVKMGYKEIEVGFPSASQT 88 
AAU      RTWPDKVITKAPRWCAVDLRDGNQALIDPMSPARKLKMFQLLVKMGYKEIEVGFPSASQT 88 
ART      RTWPDKVITKAPRWCAVDLRDGNQALIDPMSPARKMKMFDLLVRMGYKEIEVGFPSASQT 88 
         *:** . :  ** *****************.   *  ** :** :*:*:******:***: 
 
 
= Location of amino acid substitutions  
= Catalytic domain 
= Subdomain II 
= Subdomain I 
= Regulatory domain 
Catalytic domain 
Catalytic domain 
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CUR      DYDFVREIIEENKIPDDVTIQVLVQAREHLIRRTFEACAGAKNVIVHFYNSTSELQRRVV 175 
CJK      DFNFVREIIEKNMIPDDVTIQVLVQAREHLIRRTFEACEGAKNVIVHFYNSTSKLQRKVV 140 
CDI      DFDFVREIIENNMIPNDVTIQVLVQAREHLIRRTFEACEGAKNVIVHFYNSTSILQRDVV 140 
CEF      DFDFVREIIEKNMIPDDVTIQVLVQAREHLIRRTFEACEGAKNVIVHFYNSTSILQRDVV 140 
SEN      DFDFVREIIEDGAVPDDVRIQVLTQCRPELIERTFASLEGAAKAVVHIYNSTSILQRRVV 176 
MLE      DFDFVREIITDGTIPDDVTIQVLTQCRPELIERTFEACENASRVIVHFYNSTSILQRRVV 140 
MTU      DFDFVREIIEQGAIPDDVTIQVLTQCRPELIERTFQACSGAPRAIVHFYNSTSILQRRVV 180 
RHA      DFDFVREIIEDGAIPDDVTIQVLTQSRPELIKRTFEACEGANKVIVHFYNSTSILQRRVV 175 
MSM      DFDFVREIIEDNAIPDDVTIQVLTQSRPELITRTFEACRGAKNVIVHFYNSTSILQRRVV 178 
SAQ      DFDFVRQLIEQDLIPDDVTIQVLTQCREHLIDRTFAALRGAKRAIVHFYNSTSTLQRRVV 161 
LXX      DFDFVRSLIEENAIPDDVTIQVLTQAREHLIKRTYDSLVGAKRAIVHLYNSTSVLQREVV 139 
KRA      DFDFVRTLIENDLIPDDVRIQVLTQAREHLIERTYESLRGAKQAIVHLYNSTSVLQRRVV 148 
RSA      DFDFVRQLIQGGHIPEDVTIQVLTQAREHLIERTYESLVGAKQAIVHLYNSTSVLQRRVV 148 
AAU      DFDFVRQLIEGGHIPDDVSIQVLTQAREHLIERTYESLVGAKQAIVHLYNSTSVLQRRVV 148 
ART      DFDFVRQLIEGNHIPDDVTIQVLTQAREHLIERTYESLVGAKQAIVHLYNSTSVLQRRVV 148 
         *::*** :*    :*:** ****.*.* .** **: :   * ..:**:***** *** ** 
 
 
 
 
CUR      FRKDKEGIKKLATDAAHLIKEIAQD-YPDTNWRWEYSPESFTGTEIEYAKEVCDAVVEVI 234 
CJK      FRKDKEAIKKLATDAAELIKTIAKD-YPDTNWRWEYSPESYTGTEVAYAKEVCDAVVEVM 199 
CDI      FRKDKAAIKKLATDAAELIKSIAVD-YPDTNWRWEYSPESYTGTELTYAKEVVDAVVAVM 199 
CEF      FRMNKDQVKTLATDAAELIKTIAQD-YPDTNWRWEYSPESYTGTEVEYAKEVVDAVVEVM 199 
SEN      FREEREGIKKIATMGAEMALEFAGK-YPDTDFRFQYSPESYTGTELSYAAEVCDAVTEIW 235 
MLE      FRADQATVKAIATDGARKCVEEAFK-YPGTHWRFEYSPESYTGTELEYAKQVCDAVGEVI 199 
MTU      FRANRAEVQAIATDGARKCVEQAAK-YPGTQWRFEYSPESYTGTELEYAKQVCDAVGEVI 239 
RHA      FKAERDVIKKIATDAATLALEEAKQ-YPDTQWRWEYSPESYTGTELEYAKEVCDAVTEVL 234 
MSM      FRADKAAIKKIATDAAELVLEEAKK-YPDTNWRWEYSPESYTGTELSYAKEVCDAVTEIL 237 
SAQ      FGLDRDGITDIATTGARLCQKYAEIHTPDTDIHYEYSPESYTGTELDYALEVCAKVIEVV 221 
LXX      FRSDRQGIVDIALAGARLCRQFEAL-APGTEIYYEYSPESYTGTELEFAADICNQALEVF 198 
KRA      FGMDEDGIVDLALQGARLCRKFEET-IPGTTVYYEYSPESYTGTELEFAARICNAVVAVF 207 
RSA      FNEDQDGIMALATQGALLCKKYQET-LTDTKITYEYSPESFTGTELDYAVRVCNAVADIF 207 
AAU      FNQDEDGILDIALQGARLCKKYEET-LTDTHITYEYSPESFTGTELEYAARVCNAIADVF 207 
ART      FNQDEDGILDIALQGARLCKKYEET-LADTHITYEYSPESFTGTELEYAVRVCNAVADVF 207 
         *  :.  :  :*  .*             *   ::*****:****: :*  :      :  
 
 
 
CUR      DPTPENPIIINLPSTVEMITPNVYADSIEWMHRNLNRRDSIILSLHPHNDRGEGVAAAEL 294 
CJK      DPTPENPIILNLPSTVEMITPNVYADSIEWMHRNLNRRDSIILSLHPHNDRGTGVAAAEL 259 
CDI      DPTPENPIIINLPSTVEMITPNVYADGIEWMHRNLNRRDSIILSLHPHNDRGTGVAAAEL 259 
CEF      DPTPENPIIINLPATVEMITPNVYADSIEWMHRNLNRRDSIILSLHPHNDRGTGVAAAEL 259 
SEN      QPTPERPVILNLPATVEMATPNVYADSIEWMHRNLSRRDSVLLSLHPHNDRGTGIAAAEL 295 
MLE      QPTPDNPIIFNLPATVEMATPNVYADSIEWMSRNLANRESVILSLHPHNDRGTAVAAAEL 259 
MTU      APTPERPIIFNLPATVEMTTPNVYADSIEWMSRNLANRESVILSLHPHNDRGTAVAAAEL 299 
RHA      QPTPENPVILNLPATVEMATPNVYADSIEWMHRNLARRDSVILSLHPHNDRGTGVAAAEL 294 
MSM      GATPDNPVILNLPATVEMATPNVYADSIEWMHRNLARRDSVILSLHPHNDRGTGVAAAEL 297 
SAQ      DPTPDHRLIVNLPATVEMAMPNVYADSIEWMHRHLPRRDSLVLSLHPHNDRGTGVAAAEL 281 
LXX      EPTPERKVIINLPATVEMATPNVYADSIEWMSRHLNHRENVILSLHPHNDRGTAVAAAEL 258 
KRA      EPTPERQVIVNLPATVEMATPNVYADSIEWMSRHLDQRENVIISLHPHNDRGTGVAAAEL 267 
RSA      EASADNQVIVNLPATVEMITPNVYADSIEWMSHNLHPREGIILSLHPHNDRGTGVAAAEL 267 
AAU      EASADKQVIINLPATVEMATPNVYADSIEWMHRNLHPREGIIISLHPHNDRGTGVAAAEL 267 
ART      EASADSQVIINLPATVEMATPNVYADSIEWMSRHLHPREGIILSLHPHNDRGTGVAAAEL 267 
           : :  :*.***:****  ******.**** :.*  *: :::********* .:***** 
 
 
 
 
 
Catalytic domain 
Catalytic domain 
Catalytic domain 
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CUR      GYMAGADRIEGCLFGNGERTGNVCLVTLGLNMLTQGVDPQIDFSDIDQIRRTVEYCNQLR 354 
CJK      GYMAGADRIEGCLFGNGERTGNVCLVTLGLNMLTQGVDPQIDFSDIDQVRRTVEYCNQLR 319 
CDI      GYLAGADRIEGCLFGNGERTGNVCLVTLGLNMFTQGVDPQIDFSDIDQIRRTVEYCNQLR 319 
CEF      GYMAGADRIEGCLFGNGERTGNVCLVTLALNMLTQGVDPQLDFSDIKHIRRTVEYCNQLR 319 
SEN      GYQAGADRIEGCLFGNGERTGNVDLVALGMNLFSQGIDPQIDFSDLDYIKRTVEHCNQLP 355 
MLE      GYHAGADRIEGCLFGNGERTGNVCLVTLGLNLFSRGVDPQIDFSNIDEIRRTVEYCNKLR 319 
MTU      GFAAGADRIEGCLFGNGERTGNVCLVTLGLNLFSRGVDPQIDFSNIDEIRRTVEYCNQLP 359 
RHA      GYQAGADRIEGCLFGNGERTGNVCLVTLGLNMFTRGVDPQIDFSNIDEIRRTVEYCNQLP 354 
MSM      GYQAGADRIEGCLFGNGERTGNVCLVTLGLNMFSRGVDPQIDFSNIDEIRRTVEYCNQLP 357 
SAQ      GLLAGADRIEGCLFGNGERTGNVDLVTLGLNLFSQGIDPMIDFSNIDEIKRTVEYCNQLP 341 
LXX      GYLAGADRIEGCLFGNGERTGNVDLVTLGVNLFTQGIDPQIDFSDIDHIKRTVEHCNQLP 318 
KRA      GYLAGADRIEGCLFGNGERTGNVDLVTLGMNLFSQGIDPQIDFSDIDHIRRTVEHCNQLP 327 
RSA      GYLAGADRIEGCLFGNGERAGNVDLVTLGLNMFSQGVDPMIDFSDIDEIRRTVEYCNQLP 327 
AAU      GYLAGADRIEGCLFGNGERTGNVDLVTLGLNMFVQGVDPMIDFSDIDEIRRTVEYCNQLP 327 
ART      GYLAGADRIEGCLFGNGERTGNVDLVTLGLNMFVQGIDPMIDFSDIDDVRRTVEYCNQLP 327 
         *  ****************:*** **:*.:*:: :*:** :***::. ::****:**:*  
 
 
 
CUR      VPERHPYGGELVFTAFSGSHQDAINKGLAAMAERDAAEDTPEDPASADSETLTEAVRNVT 414 
CJK      VPERHPYGGDLVFTAFSGSHQDAINKGLDAIAEKIDPD-------ATAEEVTQEAMVEKT 372 
CDI      VPERHPYGGDLVFTAFSGSHQDAVNKGLDAMASRVHPG-------ATHTEVSWDELRGET 372 
CEF      VPERHPYGGDLVFTAFSGSHQDAINKGLDALAAKVKPG-------ASSTEVAWEELRSTE 372 
SEN      VHERHPWGGELVYTAFSGSHQDAINKGLNALREEAAKA--------------GAEVDAHP 401 
MLE      VHERHPYGGDLVYTAFSGSHQDAINKGLDQMKIDADAA--------------DSDVDDIL 365 
MTU      VHERHPYGGDLVYTAFSGSHQDAINKGLDAMKLDADAA--------------DCDVDDML 405 
RHA      VHERHPYGGDLVYTAFSGSHQDAINKGLDAMKFDADSQ--------------DADVDDIL 400 
MSM      VHERHPYGGDLVYTAFSGSHQDAINKGLDQMKVDADAA--------------GADMDDIL 403 
SAQ      VHERHPYVGDLVYTAFSGSHQDAIKKGFDALSADAATA--------------GVPVEKHS 387 
LXX      VGERSPWGGDLVFTAFSGSHQDAIKKGFEAMAARAQRE--------------SVDVDDLV 364 
KRA      VGERVPYGGDLVFTAFSGSHQDAIKKGLEAMERDAAAA--------------GKTVDEIP 373 
RSA      APERMPYGGDLVFTAFSGSHQDAIKKGFEALERDADAA--------------GIAVADTV 373 
AAU      VPERSPYGGDLVFTAFSGSHQDAIKKGFEALEKDAAAA--------------GKSVDDFT 373 
ART      VAERSPYGGDLVFTAFSGSHQDAIKKGFEALEKDAAAA--------------GKDVADYT 373 
         . ** *: *:**:**********::**:  :                        :     
 
 
 
CUR      WEVPYLPIDPKDIGRSYEAVIRVNSQSGKGGVAYIMKTDHNLDLPRPMQVEFSGIVQAVT 474 
CJK      WEVPYLPIDPKDVGRSYEAVIRVNSQSGKGGVAYIMKTDHNLQLPRPMQVEFSSVVQAVT 432 
CDI      WEVPYLPIDPKDVGRNYEAVIRVNSQSGKGGVAYIMKTDHGLALPRPMQVEFSSIVQEVT 432 
CEF      WEVPYLPIDPKDVGRDYEAVIRVNSQSGKGGVAYIMKTDHGLKMPRSMQVEFSAVVQNVT 432 
SEN      WEVPYLPIDPKDVGRSYEAVIRVNSQSGKGGVAYIMKTEHQLDLPRKMQIEFSKLVQART 461 
MLE      WQVPYLPIDPRDVGRTYEAVIRVNSQSGKGGVAYIMKADHGLELPRRLQIEFSRAIQKIS 425 
MTU      WQVPYLPIDPRDVGRTYEAVIRVNSQSGKGGVAYIMKTDHGLSLPRRLQIEFSQVIQKIA 465 
RHA      WAVPYLPIDPKDVGRTYEAVIRVNSQSGKGGVAYIMKADHGLVLPRRLQIEFSQAVQRIT 460 
MSM      WQVPYLPIDPKDVGRTYEAVIRVNSQSGKGGVAYIMKADHGLVLPRRLQIEFSQVIQQIT 463 
SAQ      WAVPYLPIDPKDLGRTYEAVIRVNSQSGKGGVAYVMQTEHQLDLPRRLQIEFSGVVQQVT 447 
LXX      WAVPYLPIDPKDLGRSYEAVIRVNSQSGKGGVAYLLKSDHALDLPRKLQIEFSGVVQAKT 424 
KRA      WAVPYLPIDPRDVGRSYEAVIRVNSQSGKGGVAYLLKAEHQLDLPRRLQIEFSRVIQERT 433 
RSA      WAVPYLPVDPKDLGRSYEAVIRVNSQSGKGGVAYLLKSEHSLDLPRRAQIEFSGVIQRRT 433 
AAU      WQVPYLPIDPKDLGRSYEAVIRVNSQSGKGGVAYLLKNEHNLDLPRRAQIEFSGVIQRRT 433 
ART      WQVPYLPVDPKDLGRSYEAVIRVNSQSGKGGVAYLLKNEHSLDLPRRAQIEFSGVIQKRT 433 
         * *****:**:*:** ******************::: :* * :**  *:***  :*  : 
 
 
 
 
 
 
 
Subdomain I 
Catalytic domain 
Subdomain II Subdomain I 
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CUR      D---AEGGEVNPKAMWDIFATEYLDRTAPVDVIS------TTVDGGQNEGEESAVTSQIE 525 
CJK      D---AEGGEVNPKAMWDIFSGEYLDRVAPIETIS------LTVDGGQNEGEEAKVTGQIE 483 
CDI      D---AEGGEVNSKNMWDIFAREYLDSTSPVEQVS------MSVNAAETENDEARIHARLI 483 
CEF      D---AEGGEVNSKEMWDIFATEYLDRSAPVEQIA------LRVENAQTENDDATITAELV 483 
SEN      D---SEGGEVTPDQMWAVFSDEYLGARTPLELVR------QRLDG---EAGDETITATVV 509 
MLE      E---GEGGEITPTEMWDVFFEEYLSPVQPLERIK------QRVNAAEEDGGSTSIAATVK 476 
MTU      EGTAGEGGEVSPKEMWDAFAEEYLAPVRPLERIR------QHVDAADDDGGTTSITATVK 519 
RHA      D---GEGGEVSPKEMWDVFHEEYLAPITPLERMK------QKVTASEEDGGTDSITATVK 511 
MSM      D---GEGGEVSPKEMWDAFSEEYLAPITPLERMR------QKVDAAEEDGGTDKITAVVK 514 
SAQ      D---NDGGEVDPQTMWEIFAGQYLLDHQTNPSVTLTDYTLAT------VDGKVEFEAVVG 498 
LXX      D---AEGGEVTSNEIWAIFQDEYLPAPETESDAKWGRFELGSTSTANENGDHVTLTVTLR 481 
KRA      D---AQGGEVSAAQIFDVFSDEYLPSGSGT--PEWGRFALRGTRSVSVVDGADTLEVDLH 488 
RSA      D---SVGGEVSADQRWEAFTDEYLPSPAGHPGGQWGRYALGSMNADTEEDGTTKLNTAMR 490 
AAU      D---AVGGEVSGAQLWQIFQDEYLPSDE--EQAQWGRYGLGSVSTETDESGAMTMNANLR 488 
ART      D---TVGGEVSGAQLWQIFQDEYLPSSK--EDGQWGRYSLGSFSTETDDDGAMTLHATVT 488 
         :     ***:     :  *  :**                              .   :  
 
 
 
CUR      FNGEAKTLKGRGNGPIAAYCDALESLGVDVEVQEYNQHARTSGDDAEAAAYVLAEVN--- 582 
CJK      FNGEGKTVQGRGNGPINAYCNALEELGYDVEVQEYSQHARTSGDDAEAAAYVLAEIN--- 540 
CDI      VNGSETTIEGHGNGPIAAYANALESLGIDVEVQEYEQHARTAGDDAEAAAYILAEVN--- 540 
CEF      VDGENQTVSGRGNGPLAAYANALESLNIDVEIQEYSQHARTSGDDAEAAAYVLAEVN--- 540 
SEN      VDGDEREITGSGNGPIAAFVDALSTVGFDVRVMDYSEHALTAGDDALAAAYLECAVG--- 566 
MLE      INGEETEISGVGNGPLAAFIDALGHVGLQVAVLDYSEHAMNAGDDAQAAAYVEASV---- 532 
MTU      INGVETEISGSGNGPLAAFVHALADVGFDVAVLDYYEHAMSAGDDAQAAAYVEASVTIAS 579 
RHA      VDGKEHEISGSGNGPLAAFVDALATIDFDVRVLDYSEHAMSAGDDAQAAAYVECAVTAPD 571 
MSM      VNGEEREIVGAGNGPLAAFCDALGALGINVNVRDYSEHAMSAGEEAQAAAYVEAEID--- 571 
SAQ      YDGERHTVTAVGNGPVDAYVNALQSLGVNVRVLDYHEHALSSGGDAQAAAYVECEVD--- 555 
LXX      DGETVSKATGEGNGPIAAFFDILNARGINVHLYDYSQHTLSASESATAAAYVEVNVD--- 538 
KRA      DDGAENTVRGTGNGPIAAFCAALGSRGVDVRVLDYAEHALSAGGDAQAAAYVECAVA--- 545 
RSA      IDGVEQRRSGSGNGPIAALLNILHDDGVDVRVLDYSEHALSEGGNASAASYVECAVG--- 547 
AAU      IDGVEVRRTGHGNGPIAALLDILHHDGVDVRVLDYSEHALSEGGSASAAAYVECAVG--- 545 
ART      VDGVQVRRTGSGNGPIAALLSILGQDGVDVRVLDYSEHALSEGGNARAAAYVECAVG--- 545 
                  . ****: *    *     :* : :* :*: . . .* **:*:   :    
 
  
 
CUR      -----------------------------------GQRVWGVGIAGSITYASLKAVTSAV 607 
CJK      -----------------------------------GAKYWGVGIASSITYASLKAITSAV 565 
CDI      -----------------------------------GKKFWGVGIAGSITYASLKAITSAV 565 
CEF      -----------------------------------GRMVWGVGIAGSITYASLKAVTSAV 565 
SEN      -----------------------------------DDVLWGVAIDSSTVKASLHAIVSAV 591 
MLE      ----------------------------------HGHTAWGVGIAPSITTASLRAVVSAV 558 
MTU      PAQPGEAGRHASDPVTIASPAQPGEAGRHASDPVTSKTVWGVGIAPSITTASLRAVVSAV 639 
RHA      ---------------------------------GRNTVVWGVGIATSITTASLRAVVSAV 598 
MSM      -----------------------------------GKTVWGVGIATSITTASLRAVVSAV 596 
SAQ      -----------------------------------GRTVWGAGVDANIVTATIRAVTSAV 580 
LXX      -----------------------------------GRRLWGVGIDADTTTASFKAVISAV 563 
KRA      -----------------------------------GRVLWGVGIDHNITTASLKAIVSAV 570 
RSA      -----------------------------------DRVLWGLGIDPNTTVSSLKAVISAV 572 
AAU      -----------------------------------ERVLWGVGIDPSTTTSSLKALISAV 570 
ART      -----------------------------------ERVLWGVGIDSNTTTSSLKAVISAV 570 
                                                ** .:  . . ::::*: *** 
 
 
 
 
 
 
 
Subdomain II Regulatory domain 
Regulatory domain 
Regulatory domain 
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CUR      NRALNS------------ 613 
CJK      NRSQDAAAGVSQGV---- 579 
CDI      NRALS------------- 570 
CEF      NRALDFKHQQLQNG--GV 581 
SEN      NRAGR------------- 596 
MLE      NRAMPR------------ 564 
MTU      NRAAR------------- 644 
RHA      NRAH-------------- 602 
MSM      NRAARA------------ 602 
SAQ      NRTR-------------- 584 
LXX      NRSVRASASSVPAELAGV 581 
KRA      NRALR------------- 575 
RSA      NRAIRDNQVD-------- 582 
AAU      NRAVRDAQA--------- 579 
ART      NRAIRDAQA--------- 579 
         **:                
 
 
 
 
 
 
 
 
 
 
= MtuIPMS 
= Residue conservation 
Regulatory domain 
= Catalytic domain 
= Subdomain II 
= Subdomain I 
= Regulatory domain 
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Appendix B 
Michaelis-Menten plots for α-IPMS variants 
MtuIPMS V551L 
 
 
 
 
 
MtuIPMS A558I 
 
 
 
  
α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
9.1 ± 0.8 46 ± 3 3.6 ± 0.1 
α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
9.7 ± 1.0 72 ± 5 3.9 ± 0.1 
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MtuIPMS A558V 
 
 
 
 
MtuIPMS A567V 
 
 
 
α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
6.7 ± 0.6 53 ± 3 4.0 ± 0.1 
α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
5.0 ± 0.4 56 ± 3 4.1 ± 0.1 
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MtuIPMS I627A 
 
 
 
NmeIPMS E353A 
 
 
 
α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
4.2 ± 0.4 40 ± 3 3.2 ± 0.1 
α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
29 ± 2 19 ± 1 11.6 ± 0.1 
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NmeIPMS E466A 
 
 
 
 
NmeIPMS E466A 
 
 
 
α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
29 ± 3 79 ± 3 9.3 ± 0.1 
α-KIV Km (µM) AcCoA Km (µM) kcat (s
-1) 
ND 750 ± 260 5.1 ± 0.7 
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